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Abstract 
The objective of this research project was to develop a drug delivery system for 
recombinant human erythropoietin (rHu-EPO), a glycoprotein hormone used in the treatment of 
renal anaemia and chemotherapy induced anaemia, using the biopolymer chitosan as the base 
component. Two types of chitosan nanoparticles were produced through ionotropic gelation 
using flush mixing with either tripolyphosphate (TPP) or carrageenan polymer. Chitosan-TPP 
and chitosan-carrageenan nanoparticles were generated under a variety of conditions to evaluate 
the effects of chitosan concentration, chitosan to anion mass ratio and solution pH on the 
nanoparticle characteristics of particle diameter, surface charge and particle size distribution. A 
statistical method of experimentation design, known as response surface modeling, was applied 
to allow for accurate manipulation of nanoparticle characteristics and to create nanoparticles with 
optimized characteristics.  
  The encapsulation and controlled release of rHu-EPO from chitosan nanoparticles was 
evaluated with chitosan-TPP nanoparticles demonstrating an encapsulation efficiency of 
43.45±0.84% and ~68% drug release within two weeks, while chitosan-carrageenan 
nanoparticles had an encapsulation efficiency of 47.97±4.10% and ~50% drug release within two 
weeks. Both types of chitosan nanoparticles exhibited improved encapsulation and release of 
rHu-EPO compared to previous results. Also, the molecular weight of the chitosan used and the 
surface charge of the nanoparticles were shown to have an effect on the encapsulation and 
release of rHu-EPO. 
 
Keywords: Chitosan, Drug delivery, Erythropoietin, Ionotropic gelation, Nanoparticles, 
Response surface modeling    
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Chapter 1 
1 Introduction 
The existence of erythropoietin (EPO) was first theorized in the early 1900s, but the 
hormonal regulator of red blood cell production was not identified until 1977 through the effort 
of Eugene Goldwasser, who after 17 years of work was able to isolate EPO through the 
purification of urine from aplastic anaemia patients [1, 2]. EPO is a glycoprotein hormone, 
produced in the renal interstitial cells of the kidney, which regulates the quantity of red blood 
cells within the body. Haemopoiesis is the biological process of blood cell formation, which is 
controlled by erythropoietin along with several other glycoproteins and paracrine peptides, such 
as thrombopoietin and interleukins [3]. The molecular weight of EPO is approximately 30-
36kDa and consists of 165 amino acid residues [4-6]. EPO’s structure contains 3 N-linked acidic 
oligosaccharides positioned at asparagines 24-, 38- and 83-, and 1 O-linked oligosaccharide at 
serine 126 (Fig. 1). These carbohydrates are comprised of fucose, mannose, N-
acetylfucoseamine, galactose and N-acetylneuraminic acid, and make up 40% of EPO’s mass, as 
well as control EPO’s half-life in the body [3, 5-7].  
Recombinant human erythropoietin (rHu-EPO) is applied in the treatment of renal 
anaemia and chemotherapy induced anaemia [8, 9]. Commercial production of rHu-EPO is done 
using Chinese hamster ovary cell lines and is a multi-billion dollars industry [1, 10]. The 
polypeptide sequence of rHu-EPO has been determined to be identical to that of human 
erythropoietin displaying full in vitro and in vivo biological activity [10, 11]. The possibility of 
rHu-EPO having tissue protective properties in organ systems, such as the cardiovascular and 
central nervous systems, after ischemic injury and during oxidative stress via mechanisms that 
include inhibition of apoptosis, decreased inflammation and promotion of angiogenesis has been 
the focus of many recent studies [12-17].  
Patient discomfort and treatment expenses are high due to rHu-EPO’s short half-life (8.5 
hours) after IV injection, which means the therapeutic agent must be administered frequently [9, 
18]. The use of rHu-EPO at high doses and or over prolonged periods of time increase the 
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patient’s risk of elevated blood pressure, thrombosis, chronic heart dilation, ventricular oedema, 
acute cardiac failure and other issues [14]. Biopolymer nanoparticles could be utilized as an 
encapsulation and controlled release vehicle in hopes of decreasing the enzymatic breakdown of 
the hormone and thus lower the clearance rate of rHu-EPO, while at the site of injury providing a 
controlled release that maintains the necessary therapeutic concentration. This method would 
also lower the systemic exposure of the patient to rHu-EPO, which is advantageous for the 
reasons described. 
The overall goal of this research project was to explore methods of encapsulating rHu-
EPO within biopolymer nanoparticles. The biopolymer chitosan (CS) was selected as the 
component of choice due its many beneficial properties and characteristics that make it an ideal 
drug excipient. Another advantage of chitosan is that due to its positive charge it is naturally 
attracted to EPO, which has a negative charge above its isoelectric point of 4.3, and chitosan has 
an affinity for the sialic acid found in rHu-EPO [19]. Chitosan has been used as a component of 
both microparticles and nanoparticles, which have been trialed as a vehicle for drug delivery in a 
variety of applications [20]. A literature review led to the selection of ionotropic gelation as the 
most desirable method of nanoparticle production due its mild process conditions. It was decided 
to produce two different chitosan nanoparticles, both produced through ionotropic gelation, using 
the gelling agents tripolyphosphate (TPP) and carrageenan (CG), and to compare their 
effectiveness as drug delivery vehicles. The nanoparticle production process was to be 
thoroughly explored with the objective of producing nanoparticles with the most desirable 
characteristics through the application of response surface modeling (RSM). The key 
nanoparticle characteristics were identified to be nanoparticle size, surface charge and size 
distribution. These optimized nanoparticles were then tested for their ability to encapsulate and 
control release rHu-EPO.    
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Figure 1-1: Primary Structure of Human Erythropoietin. 
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Chapter 2 
2 Nanotechnology in Drug Delivery 
Nanotechnology is a multidisciplinary field, which has shown explosive growth over the 
last few decades, and involves the engineering and manufacturing of materials at the atomic and 
molecular scale. Nanotechnology has been defined, by the National Nanotechnology Initiative, 
as structures of approximately 1-100nm in size in at least one dimension, but it has become 
common to refer to structures that are up to several hundred nanometers in size and that are 
generated through either top-down or bottom-up engineering of individual components as 
nanomaterials [21]. One of the major areas of expansion has been related to applications in the 
field of drug delivery. Drug delivery is the technique or process of administering a 
pharmaceutical compound or therapeutic agent to humans or animals in order to treat a condition 
or disease. There are hundreds of pharmaceuticals developed every year costing tens of millions 
of dollars to develop and although a substantial amount of these pharmaceutical compounds are 
approved by governing bodies for clinical applications, their method of administration has 
remained fundamentally unchanged. These methods consist mainly of drug molecules in their 
native form being administered through various routes, including oral, topical or intravenous 
injections. At the same time, the major pharmaceutical companies are saying that the rate of 
generation of new pharmaceuticals is decreasing and due to patent legislation (Hatch-Waxman 
Act) the generic pharmaceutical companies are successfully challenging their patents. Both of 
which could have sever negative effects on pharmaceutical revenues and R&D as a whole [22]. 
With these issues and the emergence of research in the field of biotechnology a significant 
interest in developing novel drug delivery systems that improve both the pharmacological and 
therapeutic properties of the original pharmaceutical compounds has formed, which has led to 
the exploration of nanotechnological improvements. The application of nanotechnology in the 
field of drug delivery has arisen due to a variety of advantages, such as lower drug 
concentrations, slower drug release, and site targeting. Nano-drug delivery systems also come in 
an assortment of structures, which include nanoparticles, both polymeric and solid lipid, 
polymeric micelles, dendrimers, liposomes, nanocrystals, metallic nanostructures, buckyballs 
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and carbon nanotubes [23, 24], that either integrate the therapeutic agent into the matrix or attach 
it to the particle surface with each having their own advantages and disadvantages. 
2.1 Why Apply Nanotechnology to Drug Delivery 
  The first advantage provided by nanoparticles is the obvious, their small size. The small 
dimensions of nano-drug delivery systems allow the particles to penetrate tissue barriers that 
large particles are unable to permeate [23]. The size of the drug delivery system is also important 
from an immune perspective because the particles must be sufficiently diminutive to avoid 
detection and clearance by the macrophage. Studies, in vitro and in vivo, have shown that both 
the size and shape of nanostructures determine their ability to cross the threshold of cells and 
tissues [25, 26], with one study finding that colloidal nanoparticles with sizes near 50nm were 
the most efficient at cellular uptake [27].  
The general goal and benefit that drug delivery systems try to achieve, nano-drug 
delivery systems are no different, is to provide a sustained and controlled release of the 
pharmaceutical agent. Figure 2-1 shows the concentration profile of a drug in the body; every 
time the drug concentration reaches cmin more drugs must be administered. Nano-drug delivery 
systems hope to provide a more stable concentration of therapeutic agent that avoids maximums 
and minimums and provides treatment over a longer period of time, in order to reduce the 
number of times medication needs to be administered. The rate of drug release from nano-drug 
delivery systems is controlled by the mass transfer characteristics of the drug carrier, which are 
affected by factors like porosity and particle degradation, and can be manipulated to alter the 
drug concentration profile within the patient. Reducing the number of times a drug must be 
administered can significantly increase patient comfort and quality of life, since many drugs 
require intrusive methods of application, such as repeated injection and intravenous 
administration. Another potential benefit of developing drug delivery systems, that can avoid 
macrophage detection and provide a controlled release, is that many drugs, such as 
chemotherapy drugs, have a variety of adverse affects on patients that reducing patient exposure 
can limit [23].   
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Figure 2-1: Typical drug concentration profile within blood. 
 
The next benefit is the potential for improved delivery of drugs that have poor water 
solubility. Nano-drug delivery systems provide the ability to encapsulate or chemically bind 
pharmaceuticals that have poor solubility or are insoluble in water, which allows for their 
transportation through water environments. Besides improving the delivery of previously 
approved therapeutic agents, the encapsulation of water insoluble drugs may allow for 
researchers to revisit previously discarded drugs, reopening a significant portion of the 
pharmaceutical tool box, and providing more and better options for treatments [21].  
One of the major reasons for the growing interest in nano-drug delivery systems is the 
potential to generate targeted delivery and triggered release of drugs to specific cells and tissues. 
Drug targeting delivery systems should be capable of controlling the fate of a drug entering the 
patient. Current delivery technologies are a long way away from the so called “magic bullet” that 
was proposed by Paul Ehrlich at the beginning of the 1900s, where the drug is precisely targeted 
to the exact site of action. The nano-drug delivery systems that have been clinically approved 
thus far are relatively simple in structure and lack targeting and/or triggered drug release 
mechanisms. Interest in the concept of drug targeting has increased greatly over the decade with 
the arrival of new technologies and better understanding of the processes behind both cellular 
and sub-cellular drug delivery [28]. Targeted delivery is divided into active and passive 
targeting, where active targeting refers to the conjugation of the drug or the carrier system to a 
tissue or cell-specific ligand and passive targeting refers to the coupling of the drug to a 
macromolecule that passively reaches the target organ [29]. Being able to target sites and release 
drugs under certain environmental conditions would prevent the release of therapeutics that may 
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have harmful side-effects in regions of the body that do not require treatment and would ensure 
that therapeutics reach their intended target.  
    There is also the potential to co-deliver two or more therapeutic agents, which would 
eliminate the need to create multiple drug delivery systems and simplify the treatment process by 
ensuring that all the necessary drugs for therapeutic treatment of a condition are working as a 
cohesive unit. Along the same stream of thought it is possible that imaging modalities also be 
included in the nanostructure to allow for simultaneous therapeutic relief and imaging. An 
example is research, by Mulder et al., where semiconductor nanocrystals, known as quantum 
dots, were conjugated to paramagnetic lipids allowing for both magnetic resonance imaging 
(MRI) and fluorescence [30]. This means that conjugating drug molecules to these nanoparticle 
surfaces can provide additional functionalities. The ultimate goal would be to use one nano-drug 
delivery system to diagnose a patient with a disease, maybe cancer, using enhanced MRI 
imaging and then use fluorescence emissions from quantum dots within the nanostructure to help 
physicians complete real-time tumour removal using optical guidance, while encapsulated drug 
molecules provide post-surgical adjuvant therapy [23]. These multifunctional nano-drug delivery 
systems, providing a universal platform for detection, imaging and delivering, will simplify 
treatment, reduce treatment time and potentially cut costs.  
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2.3 Nano-Drug Delivery Systems 
As previously mentioned, there are a variety of nano-drug delivery systems and some of 
the systems that will be reviewed are shown in Figure 2-2. 
 
 
 
A) B) 
Magnetic 
Core 
Polymer Shell 
C) D) 
 
E) F) 
Therapeutic Agent Targeting Molecule 
Hydrophilic Functional Group 
Figure 2-2: Examples of nano- drug delivery systems: A) Polymeric nanoparticles/micelles, B) Liposome, C) Dendrimers, 
D) Magnetic nanoparticles, E) Carbon nanotubes and F) Buckyballs.  
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2.3.1 Polymeric Nanoparticles 
 The application of biodegradable polymers in the formation of nanoparticles is an area of 
drug delivery that has garnered much attention over the last few decades. Nanoparticles are 
known as solid colloidal particles made up of a large polymeric structure and are in the range of 
10nm to 1000nm in size [29]. Nano-polymer drug delivery systems can come in the form of 
nanoparticles, nanospheres or nanocapsules depending upon their method of preparation and 
either dissolve, entrap, adsorb, attach or encapsulate therapeutic agents in their structure [29].  A 
nanosphere physically holds and uniformly disperses drug within its matrix system, while a 
nanocapsule confines the drug to the space within the polymer membrane of its vesicular system. 
The structure and method of drug capture define the structural properties and the release 
characteristics of the drug.  
 Polymeric nanoparticles are of particular interest for development of efficient drug 
delivery systems for release within the cytoplasmic environment. Firstly, the tiny dimensions of 
nanoparticles allow them to access smaller capillaries and to be taken up by cells, which improve 
drug accumulation at the target site [31]. The biodegradable materials used in formation of the 
nanoparticles permit sustained release of the therapeutic agent over a longer period of time, days 
or weeks, at the target site. These theories were observed in action, when dexamethasone-loaded 
nanoparticles were able to provide greater and sustained antiproliferation in vascular smooth 
muscle cells than drug within solution [32]. Polymeric nanoparticles have also been applied to 
the delivery of antigens for vaccination, since there are problems with rapid vaccine degradation 
and limited uptake by immune cells. Studies have demonstrated that polymeric micro and 
nanoparticles systems reduce vaccine degradation and improve cellular uptake [33, 34]. Another 
area of application for nanoparticles is in the delivery of therapeutic agents across the blood-
brain barrier, which has long been a challenge and held up treatment of diseases, like human 
immunodeficiency virus (HIV). Poly-(butylcyanoacrylate) nanoparticles coated with polysorbate 
80 have been demonstrated as an efficient method of transporting hexapeptide dalargin and other 
agents into the brain [35]. Further, enhancement of polymeric nanoparticles through the 
application of both active and passive forms of targeted drug delivery has been investigated [36]. 
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2.3.2 Polymeric Micelles 
 Amphiphilic block copolymers that are capable of self-associating to form micelles in 
aqueous solution are a type of polymeric nano-drug delivery system that has gained interest in 
the past decades and has been extensively studied as a drug carrier. When compared to 
conventional surfactant micelles, polymeric micelles have a few advantages over their 
counterparts in that they provide enhanced thermodynamic stability in physiological solution, 
which is indicated by their low critical micellar concentration.  This generates polymeric 
micelles’ stability and prevents their rapid dissociation in vivo [37]. Micelles have a reasonably 
narrow size distribution, with sizes less than ~100nm, and are distinguished by their distinctive 
core-shell structure, where the hydrophobic elements are kept out of contact with the exterior 
aqueous environment. Micellar systems, like liposomes to be discussed later, are useful for the 
systemic delivery of water-insoluble drugs. The micellar structure allows for the (hydrophobic or 
lipophilic) drug to be stored in the hydrophobic core of micelles and the outer hydrophilic layer 
to form a stable dispersion in the aqueous media, which can then be intravenously administered. 
The size and surface properties dictate the distribution of the drug loaded polymeric micelles 
within the body. Polymeric micelle drug delivery systems are able to avoid renal exclusion and 
the reticulo-endothelial system (RES) and exhibit enhanced endothelial cell permeability around 
solid tumour sites due to their small dimensions [38].  
It has been demonstrated that polymeric micelles that have been administered 
intravenously have an extended circulation time due to their smaller size and hydrophilic shell, 
which reduce the micelle uptake by the RES. Also, polymeric micelle drug carriers may provide 
a greater accumulation of drug than free drug in tumours and have demonstrated a reduced 
circulation to non-targeted areas.  
Polymeric micelles may also be improved by the addition of targeting mechanisms 
through conjugation of targeting ligands, including antibodies, to the micelle surface. Anti-
tumour antibody-conjugated polymeric micelles, known as immunomicelles, used to encapsulate 
the water-insoluble drug Taxol within the hydrophobic core of the micelles were successfully 
recognized and bound to a variety of cancer cells in vitro [19]. This study also confirmed that 
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immunomicelles in contrast to non-targeted micelles had the ability to deliver higher 
concentrations of drugs to mice tumours. 
2.3.3 Dendrimers 
 Dendrimers are macromolecular compounds that consist of a series of branches around an 
inner core. More specifically, dendrimer molecules are monodisperse symmetric 
macromolecules constructed about a minute molecule or linear polymer core through connectors 
and branching units. The nanometer size range of dendrimers, like all nano-drug delivery 
carriers, are one attractive aspect that makes them interesting as a drug delivery system, but they 
also provide ease of preparation and functionalization, as well as possess the ability to present 
multiple copies of surface groups for biological reorganization processes [29]. For the most part, 
interaction between the dendrimer macromolecules and the molecular environment is controlled 
by their terminal groups; thus, through modifications to their termini, the interior of a dendrimer 
can be made hydrophobic, while the exterior surface is hydrophilic, or the opposite. Dendrimers 
can be manufactured through either divergent synthesis, where construction starts from the 
central core and works outwards to the periphery, or convergent synthesis, where construction 
begins in a top-down approach with formation of the exterior residues. Due to the type of 
monomers used in dendrimer production each layer of branching units doubles or triples the 
number of peripheral functional groups. Dendrimers’ globular shape and internal cavities allow 
for encapsulation of drugs within the macromolecule interior, which combined with their ability 
to attach drugs to surface groups gives them two modes drug capture. An advantage of 
dendrimers in their water-soluble form is their ability to bind and solubilize small molecules, 
deliver drugs to specific sites in the body and act as means of timed release for biologically 
active agents.  
2.3.4 Liposomes 
 Liposomes have been employed as an adaptable tool in the fields of biochemistry and 
medicine, since they were initially proposed for use as a drug delivery carrier in 1969 [39]. The 
achievements of liposomes as a nano-drug delivery system have to date been much greater than 
any other nano system. Liposomes are spherical in shape, small in dimension and can be created 
12 
 
using natural non-toxic phospholipids and cholesterols. Liposomes are considered to be 
promising drug delivery carriers because of their hydrophobic and hydrophilic bilayer, as well as 
their biocompatibility. The properties of liposomes depend significantly on the lipid 
composition, size, surface charge and the production method. Liposomes are categorized into 
three groups dependent on their number of bilayers and size. Small unilamellar vesicles (SUV) 
contain a single lipid layer and have a diameter between 25–50 nm, while large unilamellar 
vesicles (LUV) also only have a single lipid layer, but are greater than 50nm in diameter [40]. 
The third category, multilamellar vesicles (MLV), is constructed with several lipid layers with a 
layer of aqueous solution between each lipid layer. The materials used to create the lipid layer(s) 
control the stability of the bilayer, as well as the bilayer’s charge. Generally, saturated 
phospholipids form more stable and fairly impermeable bilayers, while unsaturated 
phospholipids from natural sources produce less stable and more permeable bilayers. The 
liposome surface charge is completely dependent on the charge of the lipid used. Liposomes 
have the ability to decrease degradation of the encapsulated drug within the patient and to reduce 
systemic toxicity [41]. Liposome surface modification using polyethylene glycol (PEG) has been 
shown to improve their circulation time in the bloodstream and has earned them the nickname 
“stealth liposomes” [42]. The surface of liposomes can also be modified with antibodies or 
ligands to allow for targeted drug delivery.  
2.3.5 Metallic Nanostructures 
 Metallic nanostructures have a history in application as biosensors and contrast probes for 
imaging, diagnostics and therapeutic purposes; colloidal gold nanoparticles are an example of 
such structures that have been explored for biosensing and imaging applications. Metallic 
nanostructures display changes in quantum mechanical properties (surface plasma resonance and 
surface enhanced Raman scattering) when the nanoparticle size is altered [43]. Another reason 
for the interest in metallic nanostructures for drug delivery applications is the relative ease with 
which biomolecules may be attached onto their surfaces using different affinity interactions, as 
well as their ability to conjugate antibody-based drugs for improved drug delivery.  
The physical properties of gold nanoparticles also allow for control over the amplitude 
and rate of drug release. An example is a study on the addition of gold nanoshells to the structure 
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of hydrogel networks.  The gold nanoshells have the ability to generate heat upon optical 
excitation of various energies.  This allowed drug release to be triggered by increasing the 
temperature above the lower critical solution temperature, which caused the hydrogel network to 
collapse. Applying gold nanoshells with different thickness allows for their dielectric properties 
to be altered; thus, yielding a method of controlling the drug release rate [44].  
Another interesting sub-group of metallic nanostructures are magnetic nanoparticles. For 
starters, magnetic nanoparticles (ferric oxide nanoparticles) have been included in the structure 
of polymeric spheres and used for encapsulation and targeted release of therapeutic agents [45]. 
Magnetic nanoparticles can be used in a method similar to a homing device, where the external 
magnetic field is manipulated to direct drugs to the targeted site, after which the polymer 
elements degrade slowly releasing the therapeutic agent [46].  
2.3.6 Nanocrystals 
 The current fluorescent markers used in research and clinical diagnostic applications have 
a number of intrinsic shortcomings, which include the requirement of colour-matched lasers, the 
fluorescence bleaching, and the lack of discriminatory capacity of multiple dyes; however,  
fluorescent nanocrystals have the potential to eliminate these issues. Nanocrystals, also known as 
quantum dots (Qdots), are crystalline clumps consisting of a few hundred atoms, coated with an 
insulating outer shell of a different material [29]. For the most part Qdots are constructed of 
atoms from group II–VI or III–V of the periodic table and by definition are particles with 
physical dimensions smaller than the excitation Bohr radius [29, 47]. These tiny particles emit an 
extremely bright fluorescence, when hit by a photon of visible light, due to their quantum-
physics all of the photon’s energy is reflected to the crystal core. It is possible to detect a cell 
carrying a single Qdot [29]. Qdots are able to absorb a wide range of light wavelengths; 
however, they emit a nearly monochromatic light whose wavelength is dependent on the crystal 
size [47]. By varying size Qdots can emit light at every wavelength from infrared to ultraviolet, 
with larger Qdots emitting red light and smaller Qdots emitting blue light. Qdots are very stable 
and less toxic than organic dyes due to their inert surface coating and can be attached to 
biological materials (cells, proteins and nucleic acids).  Qdots can be incorporated into other 
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nanomaterials to make a hybrid nanoparticle that has the potential to be used for diagnostic, 
imaging and therapeutic applications all at once. 
2.3.7 Buckyballs and Carbon Nanotubes 
 The discovery of fullerenes, which were a new allotropic form of elemental carbon, other 
than diamond and graphite, in the 1980s acted as a catalyst in spurring the development of 
nanotechnology. One of the major obstacles for the application of fullerenes as drug carriers is 
their hydrophobic nature; however, research has shown that by functionalizing the surface of 
buckyballs with hydrophilic groups, such as carboxylic (-COOH) and primary amines (NH3), it 
is possible to make these fullerenes water miscible [48]. These functionalized buckyballs are 
capable of penetrating cell membranes and other barriers, like the blood-brain-barrier, which 
allows for drug delivery to sites beyond the realm of traditional drug delivery systems. 
Buckyballs have been shown to be swiftly distributed within a variety tissues and organs upon 
intravenous injection [49]. Also, chemotherapy drugs have demonstrated an affinity to 
functionalized buckyballs, with conjugated paclitaxel exhibiting a half-life in bovine plasma four 
times that of free paclitaxel [50]. 
Carbon nanotubes are cylindrical fullerenes that are hydrophobic in nature; thus, like 
buckyballs they require functionalization of their surfaces with biocompatible groups to be 
water-miscible. A few strategies for rendering them water-miscible have arisen, including strong 
acid-based oxidation through reductive chemistry, which yields surfaces with carboxylic groups. 
Another method applies diazonium chemistry to attach functional groups to their side walls using 
covalent linkages. Functionalized carbon nanotubes can be associated with a variety of 
molecules, including peptides, nucleic acids, proteins and therapeutic agents allowing for 
delivery [23]. Carbon nanotubes are able to efficiently enter cells, which has lead to their 
involvement in gene therapy. 
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2.4 Challenges of Applying Nanotechnology 
Despite all of the advantages and potential of applying nanotechnology to drug delivery 
there are still quite a few road blocks that need to be overcome. Firstly, there are concerns about 
the biosafety of some of the nano-vehicles, which means products like fullerenes, Qdots and 
metallic nanoparticles application in medicine are many years away due to this problem. The 
biosafety problems arise from inadequate biocompatibility, poor solubility and lack of 
biodegradability properties of the previously mentioned particles, which could lead to serious 
problems if applied to long term patient therapy [23, 24]. The applications of these particles in 
their current form may be acceptable for short term (1-2 weeks) or single dose scenarios without 
serious side-effects; however, this seriously limits their usefulness [24].   It has been reported 
that fullerenes induce cellular cytotoxicity in vitro. Qdots are composed of heavy metal ions 
(cadmium, selenium, etc.), which means when oxidation or enzymatic degradation of the 
nanocrystals occur these toxic heavy metal ions may be released [23].  Another reason for 
concern is that due to the nanoparticle size and physical characteristics they are able to take on 
catalytic properties when in vivo, which generates and enhances their toxic effects. Also, the 
ability to be engulfed, which is due again to physical characteristics, presents more problems as 
the likelihood of direct damage to cell internals is increased
 
[24].  
 The very promising, magnetic targeted nanoparticles have made great progress during in 
vitro and small animal testing; however, there are critical challenges when applied to larger 
animals that need a solution. One of the major issues is that when using the present technology of 
rare earth magnets it is not possible to reach nanoparticle targets that are further than a few 
centimeters from the magnet, due to the considerable increase in the magnetic field gradient with 
an increase in distance, which produces more rapid field strength decay further from the core 
[23].  Other forms of targeted delivery face issues with the host identifying the particles as 
foreign due to their surface properties, which results in their detection by the RES. These 
particles also have problems with adsorption of plasma proteins onto their surfaces that mark 
them for phagocyte removal (known as opsonisation) [23]. 
 Another major hurdle when considering commercialization is large scale production of 
nanoparticles, which has provided considerable difficulty in up-scaling laboratory methods to 
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commercial standards. There are some companies capable of producing fullerenes on an 
industrial scale, Carbon Nanotechnologies and Sumitomo; however, they have had difficulty 
producing surface modified products [51]. These problems are even more challenging for 
processes applying a bottom – up approach.   
2.5 Conclusions 
 The nanotechnology revolution has begun and shows enormous promise in the field of 
drug delivery. Nanotechnology has the potential to improve patient quality of life through 
decreased administrations due to longer drug release profiles and decreased side-effects due to 
reduced concentrations of toxic medications and targeted delivery. The ultimate drug delivery 
system that provides a universal platform for diagnosis, imaging and therapeutic treatment is 
another lofty goal that may be achieved through the application of nanotechnology. Although 
nanotechnology has great potential and has shown positive results, there are still quite a few 
obstacles affecting their successful application including possible toxicity issues and challenges 
with large-scale production. Based on the literature review of nanotechnology in drug delivery it 
was decided to proceed with the intention of developing a nanoparticle drug delivery system for 
the encapsulation and controlled release of rHu-EPO. Liposomes and polymeric nanoparticles 
were selected as the most suitable due to their biocompatibility and non-toxic nature.      
 
 
 
 
 
 
 
17 
 
Chapter 3 
3 Chitosan-based Nano-Drug Delivery Systems 
Chitosan is a polysaccharide that has been used in a variety of industries, including waste 
water treatment, cosmetics, food and nutrition, photography, textiles, and the medical and 
pharmaceutical industries. Within the medical and pharmaceutical industries, chitosan has been 
applied to ophthalmology, artificial skin generation, chitosan-based wound dressings and drug 
delivery [52]. Chitosan is comprised of repeating β-(1-4)-linked D-glucosamine and N-acetyl-D-
glucosamine units (Fig. 3-1) generated by the alkaline N-deacetylation of chitin [53, 54]. 
Chitosan is available in molecular weights ranging from 3000 to 20000 Da and percent 
deacetylated from 66 to 95% [55]. Chitin is the major structural component of crustaceans’ 
exoskeletons and as such is second only to cellulose as the most abundant polysaccharide, 
making chitosan a readily available and cheap biopolymer [53]. Chitin itself is structurally 
similar to cellulose, but is chemically inert limiting it applications. The main difference between 
chitosan and cellulose is that chitosan is composed of 2-amino-2-deoxy-h-d-glucan combined 
with glycosidic linkages and the primary amine groups are the source of the properties that 
spawn chitosan’s usefulness in pharmaceutical applications [55].  Chitosan is a weak base 
polysaccharide and a cation in acidic solutions, due to its free amine groups which become 
protonated, making it water soluble.  
Interest in the application of natural polymers as components of drug delivery systems 
has greatly increased over the past decade. Natural polymers have distinct advantages over their 
synthetic counterparts; commonly natural polymers are non-toxic, biodegradable and allow for 
cell-specific targeting. Chitosan is biocompatible with living organisms and tissues as it does not 
cause any allergic or rejection reactions and is biodegradable since it breaks down gradually 
leaving harmless amino sugars that the body absorbs, as its products [55]. The mucoadhesive 
[56, 57, 58] and low toxicity [58, 59, 60] properties of chitosan have been well documented and 
have fuelled the continual investigation of chitosan drug delivery systems. Chitosan’s 
mucoadhesive properties increase the residual time at the site of absorption; thus, increasing 
efficiency of drug delivery. Unlike many hydrophobic and amphiphilic polymers, such as poly 
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(lactide-co-glycolide) (PLGA) and poly(lactic) acid (PLA)–poly(ethylene)glycol (PEG),  
chitosan can avoid the use of hazardous organic solvents during the nanoparticle production 
process because it is soluble in aqueous acidic solution [61].  Chitosan’s free amine groups and 
cationic nature allow for ionic crosslinking with multivalent anions for the production of 
nanoparticles. Chitosan’s positive charge also allows for particles to act as permeation enhancer 
across epithelial cell membranes. It is because of these many benefits and advantageous 
properties that chitosan is of particular interest in the field of nano-drug delivery. Chitosan as a 
base component has been explored for use in buccal, intestinal, nasal, periodontal, wound 
healing and many other drug delivery systems [61], which have taken the form of beads [62], 
microcapsules [54], microspheres [54], nanoparticles [63, 64] and tablets [65].  
 
Figure 3-1: Structure of Chitosan a) Monomer b) Cross-linked chitosan. 
3.1 Methods of Producing Chitosan Nanoparticles 
There are a variety of methods that can be used to produce chitosan nanoparticles, 
including coacervation/precipitation, emulsion-droplet coalescence, ionotropic gelation and 
reverse micellar methods. When selecting a method the requirements for particle size, thermal, 
structural and chemical stability, residual toxicity, polydipsersity, and the release kinetics of the 
final product must be considered. Method selection also depends on the intended therapeutic 
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agent for delivery, as well as the nanoparticle patient application procedure. The four previously 
mentioned production methods will be described, as they are currently the most used procedures.  
3.1.1 Coacervation/Precipitation 
 The coacervation/precipitation method is based on the physical and chemical properties 
of chitosan, which make it insoluble in alkaline pH medium. This insolubility in alkaline medium 
means that chitosan precipitates/coacervates out of solution when mixed with an alkaline 
solution. One method of applying these principles to generate chitosan nanoparticles is to blow 
chitosan solution into an alkali solution using a compressed air nozzle. Commonly sodium 
hydroxide, NaOH-methanol or ethanediamine alkali solutions are used. The particles are 
separated and purified either through filtration, centrifugation or both and are then put through 
successive washing with hot and cold water [55]. The particle size is controlled through altering 
the compressed air pressure and/or the spray-nozzle diameter. The release mechanics can be 
altered through the addition of a crosslinking agent, such as glutaraldehyde, to harden the 
particles. This method is most commonly used for microparticle production, but can be applied 
for nanoparticle production.  
The method that is most frequently used for chitosan nanoparticle production is known as 
complex coacervation. This method involves the rapid mixing of chitosan solution with drug 
loaded alkali solution. In particular chitosan- deoxyribonucleic acid (DNA) nanoparticles for 
transfection applications have been produced using this technique. One such study mixed equal 
volumes of chitosan solution and preheated (50-55°C) DNA and sodium sulphate solution, at pH 
of 5.5, through vortexing for 15-30 seconds [66]. This study investigated the key factors of 
DNA, chitosan and sodium sulphate concentration, temperature, pH, amino to phosphate ratio 
and chitosan and DNA molecular weight. Nanoparticles with narrow size distributions and 
particle size between 100–250 nm were produced when the amino to phosphate group ratio was 
between 3 and 8 and chitosan concentration was 100µg/mL. This study also showed that the 
particle surface charge (zeta potential) was between +12 to +18 mV for pH levels lower than 6.0, 
but became more neutral with an increase in pH above this level. Another study of chitosan-
pDNA particles produced particles with particle size between 450-820nm, surface charge of +9 
to +18mV, encapsulation efficiency between 90.4 and 98%, depending on chitosan’s degree of 
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deacetylation, and complete release within 24hr in phosphate buffered saline solution (PBS) [67]. 
Both studies showed chitosan–DNA nanoparticles could partially protect the encapsulated 
plasmid DNA from nuclease degradation.  
3.1.2 Emulsion-droplet Coalescence 
 The emulsion-droplet coalescence method employs both precipitation and emulsion 
cross-linking principles. Unlike the emulsion cross-linking methods applied to produced chitosan 
microparticles, which cross-links stable droplets, in this method precipitation is induced by 
allowing the merging (coalescence) of chitosan droplets with NaOH droplets. This method was 
first utilized by Tokumitsu et al [68]. The first step is to produce a stable emulsion containing 
aqueous chitosan and therapeutic agent solution, which is generated in liquid paraffin oil. The 
same process is used to produce another stable emulsion containing chitosan aqueous solution in 
NaOH. Then the emulsions are mixed using high-speed stirring, which causes random collisions 
and coalescence of droplets from each emulsion; thus, precipitating chitosan droplets and 
producing nanoparticles.  
Tokumitsu et al encapsulated gadopentetic acid using this method for gadolinium 
neutroncapture therapy [68]. They found that particle size depends upon the degree of chitosan 
deacetylation, which as it decreased the particle size increased, while drug encapsulation 
efficiency decreased. However, increasing the gadopentetic acid concentration in the chitosan 
solution did not increase the particle size and did increase the encapsulation efficiency. Their 
investigation produced nanoparticles with a mean particle size of 452 nm and 45% gadopentetic 
acid loading using 100% deacetylated chitosan. It should be noted that the nanoparticles were 
obtained within the emulsion-droplet and that the size of the nanoparticles was not connected to 
the droplet size. This is a prime example of selecting the production process based on all factors 
including drug properties. The gadopentetic acid is a bivalent anionic compound which 
electrostatically interacts with the amine groups of chitosan; however, this interaction would not 
happen if a particle production method that utilizes a cross-linking agent that blocks the free 
amine groups of chitosan was used. Therefore, by using the coalescence method the 
encapsulation efficiency is optimized. 
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3.1.3 Reverse Micelles 
Reverse micelles are mixtures of water, oil and surfactant that are thermodynamically 
stable and have a dynamic behaviour. When viewing up-close at the microscopic scale, the 
structure of reverse micelles consists of aqueous and oil volumes separated by surfactant films, 
as the observer zooms out to a more macroscopic scale reverse micelles appear homogeneous 
and isotropic. The advantage of reverse micellar formation is that ultrafine polymeric 
nanoparticles with narrow size distributions are produced, while applying traditional emulsion 
polymerization methods larger nanoparticles (>200nm) are formed with broad size distributions 
[55]. The reverse micelle aqueous core acts as a nanoreactor in preparation of ultrafine 
nanoparticles. The minute dimensions and narrow size distribution of nanoparticles produced 
through the reverse micellar method are due the small size of the reverse micellar droplets 
themselves, which are usually between 1 and 10 nm in dimension, and their high degree of 
monodispersity [55]. Reverse micelles experience continuous coalescence and re-separation on a 
timescale that fluctuates from milliseconds to microseconds due to their constant Brownian 
motion. Thus, through a rapid dynamic equilibrium the system is able to preserve its size, 
polydispersity and thermodynamic stability. 
When performing the reverse micelle method, surfactant is first dissolved in an organic 
solvent in order to create the reverse micelles and then the chitosan and drug aqueous solution is 
added under constant vortexing to avoid any turbidity. The system can be manipulated based on 
the amount of aqueous phase and the generally aqueous phase is maintained at a level where the 
entire mixture is an optically transparent microemulsion. The aqueous phase also dictates the 
particle size, with an increased amount of water larger nanoparticles are obtained. Like any type 
of nanoparticle system the maximum drug loading varies between different therapeutic agents, 
but reverse micelles maximum drug loading can be found by gradually adding drug until the 
clear microemulsion is converted into a translucent solution. The next step is to add a cross-
linking agent under constant stirring and mix overnight to allow for complete cross-linking to 
occur. A transparent dry mass is collected by evaporating the organic solvent, after which the 
mass is dispersed in water and an appropriate salt is added to precipitate out the surfactant. The 
mixture is then centrifuged in order to collect the drug loaded nanoparticles. Finally after being 
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re-suspended in aqueous solution it is immediately dialyzed through a dialysis membrane for 
approximately 1 h and the liquid is freeze dried leaving a dry powder.  
3.1.4 Ionotropic Gelation 
Ionotropic gelation is a process where a polyelectrolyte is cross-linked with a counter ion 
forming a hydrogel. The structures of hydrogels are maintained by hydrogen bonding, 
hydrophobic forces, ionic forces or molecular entanglements [69]. This technique has been 
applied using a variety of materials, including gellan gums, alginates, carboxymethyl cellulose 
and chitosan, to create micro and nanoparticles for encapsulation and controlled release of 
therapeutic agents [70]. Depending on the material used, the strength of the counter ion and the 
desired particle size several methods of ionotropic gelation can be applied, including syringe 
dropping and air atomization for bead formation [70], and flush mixing for nanoparticles 
formation [63]. The application of ionotropic gelation, which utilizes chitosan’s positive charge 
to cross-link it with an anion, to form micro- and nanoparticles has garnered much attention 
because the process is very simple and takes place under mild conditions. The mild conditions 
refer to the lack of possible toxic reagents and other undesirable effects associated with chemical 
cross-linking when compared to reversible physical cross-linking by electrostatic interaction. 
The most well documented chitosan nanoparticles produced through ionotropic gelation are 
chitosan-tripolyphosphate nanoparticles, which many research groups have explored as a 
potential drug delivery system for various drugs [63, 64]. Potential anions are TPP, sodium 
alginate, κ-carrageenan and hexadesyl sulphate. When applying the ionotropic gelation process 
to chitosan it is first dissolved in aqueous acidic solution, obtained using acetic acid, which 
generates the chitosan cations. The chitosan solution is added drop wise under constant stirring 
to polyanionic solution (ie.TPP), which through the ionic interaction between the oppositely 
charged species, chitosan precipitates to form spherical particles. 
Fernandez-Urrusuno et al. prepared insulin loaded chitosan-TPP nanoparticles by adding 
insulin to the TPP solution prior to mixing with the chitosan solution [63]. The studied used two 
different molecular weight chitosans and the chitosan to TPP mass ratio used was 6:1. The 
resulting nanoparticles had a mean particle size between 300–400 nm, a surface charge between 
+25 to +54 mV and insulin loading as high as 55%. Another group investigated the intestinal 
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absorption of insulin in vivo when delivering using chitosan-TPP nanoparticles [71]. The 
intention was to determine if the bioadhesive properties of chitosan would further enhance 
insulin’s intestinal absorption. The insulin-loaded chitosan-TPP nanoparticles were prepared 
through ionotropic gelation producing particles that were positively charged, had a particle size 
between 250– 400 nm, polydipsersity less than 0.1 and an insulin association of up to 80%. The 
insulin loaded chitosan-TPP nanoparticles were orally administered to alloxan-induced diabetic 
rats and through monitoring the plasma glucose levels the intestinal adsorption of insulin was 
tracked. The chitosan-TPP nanoparticles improved the intestinal absorption of insulin more than 
aqueous solution of chitosan in vivo and after administration of nanoparticles with 21 I.U/kg of 
insulin hypoglycemia was prolonged over 15 hrs. The average pharmacological bioavailability 
relative to SC injection of insulin solution improved 14.9%. The in vitro release experiments 
indicated an initial burst effect, which is pH-sensitive. Another study would go on to the show 
that insulin encapsulation efficiency is highly dependent on the pH with encapsulation 
efficiencies ranging between 2 and 85%, with the highest obtained at a pH of 6.1 [72]. This study 
also showed that the release of insulin was pH dependent.     
3.2 Drug Delivery Applications of Chitosan Nanoparticles 
 As mentioned in the introduction, chitosan has been used in a large number of drug 
delivery systems covering a variety of applications with different therapeutic goals and 
application regions of the human body. Chitosan nanoparticles have for the most part contributed 
to drug delivery research in the fields of cancer therapy, gene delivery and ocular delivery. One 
example of their application to cancer therapy is the previously mentioned gadopentetic acid 
delivery system that was used for delivery to tumour sites for gadolinium neutroncapture therapy 
[68]. Another cancer therapy system that was explored is chitosan nanoparticles loaded with 
doxorubicin-dextran conjugate, which showed reduced side-effects and increased therapeutic 
efficiency on solid tumours [73].  
Gene therapy or gene delivery involves plasmid DNA being introduced to specific cells, 
where through the transcription and translation processes the genetic information is used to 
produce the desired proteins. This process, otherwise known as transfection, is challenging and 
must overcome several obstacles before the desired results can be obtained. The first challenge in 
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gene delivery is successfully targeting the specific type of cells that require transfection. Once, 
the desired cells have been reached the delivery system must transport the plasmid DNA through 
the cell membrane.  The DNA delivery system must avoid uptake and degradation by 
endolysosomes and the final challenge is to navigate intracellular trafficking to the nucleus. As 
mentioned in the coacervation/precipitation section, chitosan and negatively charged DNA can 
interact ionically to form nanoparticles, which provide better protection for DNA against 
nuclease degradation and increase transfection efficiency [66, 67]. A more recent study on the 
oral application of chitosan nanoparticles for delivery of DNA demonstrated a 5 fold increase in 
nanoparticle transport through the M-cell co-culture model when compared to transport through 
intestinal epithelial monolayers and that the addition of surface modifiers, in this study 
transferrin, increases the transport 3-5 fold [74].  
Delivery of therapeutic agents to the ocular region is another area of interest for chitosan 
nanoparticles. A study focusing on the delivery of the immunosuppressant cyclosporine A to the 
ocular region applied chitosan nanoparticles with a mean size of 293nm and surface charge of 
+37mV for their purposes [75]. This study found that in vivo experiments applying cyclosporine 
A loaded chitosan nanoparticles in a topical manner to the ocular region of rabbits, produced 
therapeutic concentrations in external ocular tissues during at least 48 hours, while maintaining 
negligible cyclosporine A concentrations in the inner ocular structures, blood and plasma. This 
showed an improvement over chitosan solution containing cyclosporine A and an aqueous 
cyclosporine A suspension. This shows great potential for applications in ocular drug delivery.  
3.3 Conclusions 
 Chitosan is a polysaccharide with tremendous upside and beneficial characteristics 
making it of great interest to the field of drug delivery. There are several methods of chitosan 
nanoparticle production that produce a variety of nanoparticles with different physical and 
chemical characteristics, which allows for tailoring to specific drugs and applications. Within the 
last 2 decades chitosan nanoparticles have already shown many positive results within a wide 
variety of drug delivery applications. Many areas of drug delivery are still showing interest in 
chitosan microparticles, so with the inherent advantages of nano-drug delivery systems, 
exploration into the nano field is the logical next step.  
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  The methods of emulsion-droplet coalescence and reverse micelles require the use of 
cross-linking agents or other undesirable compounds that make them non-ideal for the purposes 
of this study. The coacervation/precipitation method of chitosan nanoparticle production did not 
apply potentially harmful chemicals, but the nanoparticles created with this method had low 
stability, which was displayed by their zeta potential (<30mV) and the 100% release of the 
therapeutic agent in the first 24 hours.  In the end, ionotropic gelation was selected as the method 
of nanoparticle production for this study because of the process’s mild operating conditions, 
simplicity and previous encapsulation results with other therapeutic agents.     
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Chapter 4 
4 Materials and Methods 
4.1 Materials 
4.1.1 Chemicals and Equipment  
Table 4-1:  List of chemicals used during this research study. 
Chemicals Catalogue Number Supplier 
Acetic Acid Cat. No. 320099 Sigma-Aldrich, Canada 
Carrageenan Cat. No. C1013 Sigma-Aldrich, Canada 
Chitosan, Low Molecular 
Weight (MW) 
Cat. No. 448869 Sigma-Aldrich, Canada 
Chitosan, High MW Cat. No. 419419 Sigma-Aldrich, Canada 
Chitosan, Medium MW Cat. No. 448877 Sigma-Aldrich, Canada 
Glycerol Cat. No. G7893 Sigma-Aldrich, Canada 
Phosphate Buffered Saline Cat. No. P5368 Sigma-Aldrich, Canada 
Potassium Chloride (KCl) Cat. No. P9541 Sigma-Aldrich, Canada 
rHu-Erythropoietin EPREX Jansen Ortho, Canada 
Sodium Hydroxide (NaOH) Cat. No. 221465 Sigma-Aldrich, Canada 
Sodium Tripolyphosphate Cat. No. 238503 Sigma-Aldrich, Canada 
Note: The low MW chitosan was from shrimp shells, 80-85% deacetylated and had a viscosity of 
20-200cP at STP. The medium MW chitosan was from crab shells, 75- 85% deacetylated and 
had a viscosity of 200-800cP at STP. The high MW chitosan was from shrimp shells, 70-80% 
deacetylated and has a viscosity of 800-2000cP at STP. The sodium tripolyphosphate was 
technical grade with 85% purity. The carrageenan used was a gel formation grade, 
predominantly κ and lesser amounts of λ carrageenan. The rHu-EPO used was clinical grade 
EPREX, which had a concentration of 40000IU/mL and came in a 1mL prefilled syringe.  
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Table 4-2: List of equipment used during this research study. 
Equipment Model Supplier 
Balance PB3002 Mettler Toledo Inc.,  
Columbus, OH, USA  
Balance, Precision BP 210S  Satorius AG,  
Mississauga, ON, Canada 
Centrifuge, Ultra Sorvall WX100 Thermo Fisher Scientific, 
Waltham, MA, USA 
Centrifuge, Ultra Optima Max, Benchtop Beckman Coulter,  
Mississauga, ON, Canada 
Fluorometer Fluorolog3 Horiba Jobin-Yvan,  
Edison, NJ, USA 
Magnetic Stirrer, Multiple Multi-position Magnetic 
Stirrer, (Cat. No. 12621-034) 
VWR International, 
Mississauga, ON, Canada 
Magentic Stirrer, Single Thermix Stirrer, 120MR Thermo Fisher Scientific, 
Waltham, MA, USA 
pH Meter Symphony, SB70P VWR International, 
Mississauga, ON, Canada 
Transmission Electron 
Microscopy (TEM) 
CM 10 Koninklijke Philips 
ElectronicsN.V., Netherlands 
Vortex Mixer Vortex-Genie Thermo Fisher Scientific, 
Waltham, MA, USA 
Water Purifier MegaPure, MP-3A Labequit Ltd., 
Markham, ON, Canada 
Zetasizer ZetaPlus with ZetaPals Brookhaven Instruments Corp., 
Holtsville, NJ, USA 
4.1.2 Description of Important Chemicals 
The important chemicals, EPO and chitosan were previously described in the Chapters 1 
and 3. Both chitosan and EPO are amphoteric proteins, also known as zwitterions, meaning that 
they contain functional groups with both positive and negative charges.  The pH of the 
surrounding environment dictates the level of protonation of their functional groups, which 
controls the molecules’ net charge. The pH at which the molecule has no charge or the charge of 
the positive and negative groups cancels out is known as the isoelectric point. For pH levels 
below the isoelectric point of a protein the net charge of the molecule is positive, while for pH 
levels above the isoelectric point the protein’s net charge is negative. As mentioned previously, 
there is a desire to maintain opposite charges between chitosan and rHu-EPO, in order to 
preserve an electrostatic affinity between the two proteins and hopefully increase encapsulation 
efficiency.  The isoelectric points of chitosan and rHu-EPO are at pH ~6.5 and pH ~4.3, 
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respectively. The net charge of the important chemical components as a function of pH is 
described in Table 4-3.   
Table 4-3: Main chemical components' net molecular charge as a function of pH. 
Chemical Component Net Charge of the Molecule 
pH < 4.3 4.3 < pH < 6.5 pH > 6.5 
Carrageenan - - - 
Chitosan + + No longer  
water soluble 
rHu-EPO + - - 
TPP - - - 
The other two major nanoparticle components were sodium tripolyphosphate and 
carrageenan. Sodium tripolyphosphate is a white, water-soluble, granular powder and is the 
sodium salt of triphosphoric acid. It is produced through the combination of monosodium 
phosphate and disodium phosphate under strict environmental conditions. TPP is a component of 
commercial detergents, with the purpose of improving surfactant efficiency, and is used in the 
preservation of foods for maintaining moisture [76]. TPP has been found to be non-carcinogenic 
and have low toxicity, with an oral LD50 of 3900mg/kg, according to the MSDS.   
Carrageenan refers to a family of gel-forming polysaccharides that are extracted from red 
seaweeds, with the most important being ι-, κ- and λ-carrageenan. ι- and κ- carrageenan are 
known as gel-forming carrageenans, while λ-carrageenan is used as a thickener. Carrageenans 
are used primarily in the food industry as gelling, thickening and stabilizing agents, but have also 
found applications in the pharmaceutical and cosmetics industries. Structurally carrageenans are 
composed of a linear galactose backbone with sulphatation range between 15 and 40%; however, 
carrageenan is mixture of linear, sulphated, water-soluble galactans rather than one biopolymer. 
Carrageenans consist of alternating 3-linked β-D-galactopyranose (G-units) and 4-linked α-D-
galactopyranose (D-units) or 4-linked 3,6-anhydrogalactose (DA-units) repeating units [77]. 
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Figure 4-1: Structure of sodium tripolyphosphate. 
 
Figure 4-2: Structure of κ-, ι- and λ- carrageenan. 
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4.2 Methods 
4.2.1 Preparation of Chitosan Nanoparticles 
Chitosan stock solutions were prepared by dissolving chitosan in 2% (w/v) acetic acid 
solution and allowing 12 hours for mixing. The chitosan solution was then filtered through 8µm 
filter paper using a vacuum system in order to remove any undissolved chitosan. The pH of the 
stock solution was then adjusted to a pH of 5 using sodium hydroxide.  
4.2.1.1 Chitosan-TPP Nanoparticles 
Chitosan solutions of 0.5mg/mL, 1mg/mL, 1.5mg/mL, 2mg/mL and 3mg/mL were 
prepared by diluting stock solution with Milli-Q purified water. The solutions’ pH levels were 
adjusted to pH 5 using 10N sodium hydroxide. Sodium tripolyphosphate was dissolved in Milli-
Q purified water to produce a stock solution with a concentration of 1mg/mL. Based on the 
chitosan concentration being used TPP solutions that would yield a final chitosan to TPP mass 
ratio of 3:1, 4:1, 5:1, 6:1 and 7:1 were prepared. The chitosan-TPP nanoparticles were generated 
through flush mixing of 5mL of chitosan solution with 5mL of TPP solution of equal pH at room 
temperature and allowed to mix for 30 minutes. Triplicates of each chitosan concentration and 
chitosan to TPP mass ratio combination were performed. 
4.2.1.2 Chitosan-Carrageenan Nanoparticles 
Chitosan solutions of 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 1mg/mL and 2mg/mL were 
prepared by diluting stock solution with Milli-Q purified water. The solutions’ pH levels were 
adjusted to pH 5 using 10N sodium hydroxide. Carrageenan was dissolved in Milli-Q purified 
water to produce a stock solution with a concentration of 1mg/mL. Based on the chitosan 
concentration being used carrageenan solutions that would yield a final chitosan to carrageenan 
mass ratio of 2:1, 3:1, 4:1, 5:1 and 6:1 were prepared. The chitosan-carrageenan nanoparticles 
were generated through flush mixing of 5mL of chitosan solution with 5mL of carrageenan 
solution of equal pH at room temperature and allowed to mix for 30 minutes. Triplicates of each 
chitosan concentration and chitosan to carrageenan mass ratio combination were performed. 
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Figure 4-3: Schematic diagram of chitosan nanoparticle production through ionotropic gelation. 
4.2.2 Chitosan Nanoparticle Physiochemical Characterization 
The mean effective diameter, particle size distribution and zeta potential of the chitosan 
nanoparticles were determined using the ZetaPlus zetasizer produced by Brookhaven Instruments 
Corp. The mean effective diameter and polydipsersity (particle size distribution) were 
determined for each sample using dynamic light scattering (DLS) with the temperature 
maintained at 20°C and 10 single measurement runs of 30 seconds in length were performed 
using a detection angle of 90° and a refractive index of 1.335. Laser doppler electrophoresis 
(LDE) was applied to determine the nanoparticle zeta potential of each sample with the 
temperature maintained at 20°C, a refractive index of 1.335 and dilution with 1mM KCl for the 
10 runs conducted per reading. The nanoparticle solution was diluted by 15 times and the diluted 
solutions had a pH of 5.5±0.1. 
4.2.2.1 Dynamic Light Scattering (DLS) 
 Dynamic Light Scattering, also known as Quasi-Elastic Light Scattering (QELS), is a 
technique applied to determine the average particle diameter, particle size distribution and 
polydipsersity index of particle dispersions. DLS measures the Brownian motion, the random 
movement of particles caused by the barraging of solvent molecules, in order to calculate the 
particle size. The Brownian motion of larger particles is less than that of smaller particles, since 
the collision of other molecules with smaller particles produces a greater transfer of energy; thus, 
more of a reaction. Typically DLS is applied to colloidal systems with particle diameters ranging 
between 3nm to 3µm, since these particles have the ability to remain suspended within solution, 
which means more importance is placed on dispersion than gravitational sedimentation.  The 
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temperature must be known and maintained stable because the viscosity, which is temperature 
dependent, is critical for the determination of particle size through DLS.  
Equation 4-1 
  
  
    
      
 The Stokes-Einstein equation (Eq. 4-1) can be used to calculate the hydrodynamic 
diameter of a particle in solution using the transitional diffusion coefficient (D), the Boltzmann’s 
constant (κ), absolute temperature (T) and the viscosity (η) [78, 79]. The translational diffusion 
coefficient is a property used to define the velocity of Brownian motion. The diameter computed 
using the Stokes-Einstein equation is the diameter of a sphere with the same transitional 
diffusion coefficient as the particle. DLS determines the speed of Brownian motion of particles 
within a colloidial system by measuring the rate of fluctuation in intensity of scattered light.   
 
Figure 4-4: Typical correlogram from a sample containing large particles and a sample containing small particles. The 
signal correlation is seen to decay more rapidly for the sample of small particles. 
The rate of fluctuation in intensity of scattered light is dependent on the particle size, with 
smaller particles causing the intensity to fluctuate more quickly than larger particles. Although, it 
is possible to directly determine the intensity fluctuations through measurement of their spectrum 
of frequencies, it is more efficient to use digital auto correlators. A correlator compares the 
correlation between signal intensity measurements over time, where a perfect correlation is 1 
(known as unity) and no correlations is denoted by 0. The larger the particles in the colloid 
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system the slower the signal changes with time and the longer the correlation persists (Fig. 4-4). 
The correlogram for a sample contains a considerable amount of information with the starting 
point of significant decay being connected to the mean particle size and the slope of decay being 
related to sample polydispersity.  The greater the slope of the correlogram for a sample the more 
monodisperse it is. The correlation function (Eq. 4-2) is used to convert the intensity signals into 
a measurement of the translational diffusion coefficient. Equation 4-2 is the correlation function 
for a suspension of large monodisperse globular particles, where A is an optical constant set by 
the design of the instrument, B is the intercept of the correlation function, Γ is related to the 
relaxation of the fluctuations and τ is time delay [78, 79]. The correlation function is constructed 
by the DLS software for polydisperse samples by replacing the term e
-2Γτ
 with the sum of all the 
exponential decays within the correlation function.   
Equation 4-2 
               
Equation 4-3 
                
Equation 4-4 
   
   
 
    
 
 
        
Equation 4-5 
                
 
  
 
In Equation 4-4, q represents the scattering vector, n represents the refractive index of the 
dispersant, λ represents the wavelength of the laser and θ represents the scattering angle. 
Through the combination of Equations 4-2, 4-3 and 4-4 the translational diffusion coefficient is 
determined and then substituted into the Stokes-Einstein equation to calculate the particle 
diameter. Variance in the correlation function is given in the form of the polydispersity index, 
which indicates the particle size distribution. In Equation 4-5, µ is a value proportional to the 
variance of the weighted translational diffusion coefficient distribution and it carries information 
about the width of the particle size distribution that is made useful through conversion into the 
polydispersity index [78, 79].  
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            A DLS device operates by directing a constant wavelength laser beam through a cuvette 
containing sample (sample cell), whose temperature is maintained constant by a thermostat (Fig. 
4-5) [79]. The laser beam is then scattered by the colloidal particles and the scattered light is 
detected by either a photomultiplier tube (PMT) or a photodiode at an angle of θ (90° for 
ZetaPlus). If the intensity of scattered light is too great the detector will become saturated or if 
there is too little scattered light for detection measurement will not be possible, which is why an 
attenuator is used to adjust the amount of scattered light to within an acceptable range. The 
detected information is subsequently sent to the correlator and analytical computer for 
processing. Figure 4-6 is an example of the typical chitosan nanoparticle measurement obtained 
using the DLS technique and the ZetaPlus instrument.   
 
Figure 4-6: Typical lognormal distribution for chitosan-TPP nanoparticles. Medium MW chitosan, chitosan 
concentration of 0.5mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C and pH 5. 
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Figure 4-5: Schematic diagram of a DLS instrument comprised of 1) laser, 2) attenuator, 3) sample cell, 4) thermostat, 5) 
photomultiplier, 6) autocorrelator and 7) analyzing computer. 
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4.2.2.2 Laser Doppler Electrophoresis (LDE) 
 Laser Doppler Electrophoresis is a method of determining the zeta potential of particles 
in solution through the measurement of the drift velocity of a colloid in a known electric field. 
Almost all particles dispersed in a liquid have a charge that will cause them to move towards 
either the positive or negative pole of an applied electric field (electrophoresis) with the direction 
of movement indicating the sign of the charge. While, the velocity with which the particles travel 
towards the pole is indicative of the magnitude of the charge. LDE measures both the direction 
and velocity of particle movement within an electric field and then calculates the mobility and 
zeta potential.  
    There are four electrokinetic phenomena that affect colloidal dispersions: 
electroosomosis, electrophoresis, sedimentation potential and streaming potential. In the 
ZetaPlus only electrophoresis is considered, since the other variables are eliminated, which 
provides an advantage over other methods that must consider multiple electrokinetic phenomena. 
During electrophoresis the particles move toward the oppositely charged electrode with an 
average drift velocity (Vs), which is proportional to the electric field strength when the field 
strength is low (Eq.4-6) [80, 81]. The mobility (µe) of a particle is indicative of the surface 
charge with a positive mobility meaning the charge is positive and a negative mobility meaning 
the charge is negative. The sign of mobility is important, but the value itself does not provide any 
information on the repulsive surface forces. However, there is no independent way of calculating 
zeta potential without mobility using the electrophoresis technique.     
Equation 4-6 
             
    
Equation 4-7 
    
  
 
               
Equation 4-8 
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There are two models, the Smoluchowski and the Huckel equations, relating mobility and 
zeta potential (ζ) that can be used within certain limits. The Huckel equation can only be applied 
when the dimensionless product κa, where a is the particle radius and κ-1 is the double layer 
thickness, is much less than one and is useful for applications with ions (Note:  κ-1 is large at low 
electrolyte concentrations and small at high electrolyte concentrations). The Smolunchowski 
equation (Eq. 4-7) is applied when κa is much larger than one, but this condition is not easily 
fulfilled by colloids either, so a general equation exists as well (Eq. 4-8) [80, 81]. Both equations 
involve the relative permittivity of the liquid (ε) and liquid viscocity (η). In practise generating 
the function and applying the general equation is too complex; thus, the ZetaPlus software 
utilizes the Smolunchowski equation for converting mobility into zeta potential.    
 
Figure 4-7: Schematic diagram of the ZetaPlus electrode comprised of gold electrodes for electric field production, a 
thermistor for temperature control, and a PC Board and connector unit for information transfer (Adapted from Weiner 
et al., 1993). 
 In order to apply the aforementioned equations to calculate the mobility and zeta 
potential, the average drift velocity of the particles must be measured first. The ZetaPlus 
measures the average drift velocity by directing a laser beam through the sample cell, where two 
electrodes (Fig. 4-7) generate an electric field. The light is scattered by the particles, moving 
perpendicular to the laser beam towards the poles of the electric field, causing a Doppler shift in 
the frequency of the scattered light. The frequency of the light is shifted proportionately to the 
velocity of the particles and contains information on the particle mobility. A part of the laser 
beam is diverted before reaching the sample cell with the purpose of creating a reference beam 
and is recombined with the scattered light leaving the sample cell. The purpose of the reference 
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beam is to determine the sign of the zeta potential by ascertaining whether the Doppler shift was 
positive or negative. Frequency is an intrinsically positive value, so the Doppler shift is 
compared to the reference beam with Doppler shifts larger than the reference beam resulting 
from positively charged particles and shifts less than the reference beam resulting from 
negatively charged particles. Most Doppler shifts are within the range of 100Hz and the ZetaPlus 
reference beam is 250Hz. The average drift velocity is calculated using Equation 4-9, where n is 
the liquid refractive index, λ is the wavelength of the laser, θ is the scattering angle and ωD is the 
Doppler shift frequency [80, 81]. 
Equation 4-9 
    
   
 
    
 
 
         
The design of the ZetaPlus zetasizer is depicted in Figure 4-8. First a laser generates a 
beam of light that is split with 90% of the beam being directed towards the sample cell and the 
other 10%, directed past the sample cell, becoming the reference beam. The beam passes through 
the sample cell in which the particles are moving perpendicular to the beam due to the electrode 
induced electric field. The light that is scattered at an angle of 15° is collected and combined 
with the reference beam, which is then measured by a PMT detector that sends the measurement 
to an analysis computer. An example of the typical chitosan-TPP nanoparticle zeta potential 
measurement obtained through LDE using the ZetaPlus zetasizer is shown in Figure 4-9. 
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Figure 4-8: Schematic diagram of ZetaPlus zetasizer comprised of 1) the laser, 2) the lens, 3) the beam splitter, 4) a 
mirror, 5) the sample cell and electrodes, 6) a mirror, 7) the beam combiner and 8) the PMT detector (Adapted from 
Weiner et al., 1993). 
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Figure 4-9: Typical zeta potential measurement for chitosan-TPP nanoparticles. Medium MW chitosan, chitosan 
concentration of 0.5mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C and pH 5. 
4.2.3 Particle Morphology – Transmission Electron Microscopy 
The chitosan nanoparticle morphology was determined using transmission electron 
microscopy with a CM 10 (Phillips, Netherlands). A single drop of chitosan nanoparticle 
solution was placed on a formvar/carbon 400 mesh grid and allowed to air-dry at room 
temperature for 1-2 minutes before analysis at 80kV.  
TEM is a popular method for viewing and imaging solid materials at the atomic level. 
The general design is similar to that of an optical microscope; however, instead of light high 
energy electrons are used and rather than glass lenses electromagnetic lenses are used. TEM 
systems are able to obtain a spatial resolution of approximately 0.1nm and typically operate at 
electron voltages of 80-120kV for conventional 2D imaging, while 150-400kV can be applied for 
electron tomography, energy filtered TEM and cryoTEM [82]. The basics of TEM are that an 
electron beam generated by a cathode and accelerated by an anode passes through a sample, the 
output pattern is magnified using a system of lenses and then the image is displayed on a 
fluorescent screen or a charge-couple device camera. 
The microscope consists of an electron gun at the top of an extended cylindrical column 
followed by two electromagnetic condenser lenses, one that focuses the electron beam and 
another lens for fine adjustments (Fig. 4-10). These first two lenses allow for control over 
brightness of the beam. The beam then passes through the condenser aperture and hits the 
sample. Electrons that hit the sample are either diverted (elastic electrons) or adsorbed by the 
sample material. The elastically scattered electrons travel through the objective lens, which 
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forms the image of the sample that then passes through the objective aperture onto the 
magnification system. There are three lenses that compose the magnification system, the first 
two magnify the image and the final lens, the projector lens, projects the image onto either a 
fluorescent screen or a charge-couple device camera. The microscope column is maintained 
under vacuum while operating.  
     
4.2.4 Statistical Analysis 
Response surface modeling is a method of statistical experiment design that allows for 
the determination of peak process performance [83]. This statistical method of experimentation 
has been applied to both industrial and academic applications to produce accurate process maps 
based on mathematical modeling. The advantage of RSM is that it allows for several factors to 
be varied at a time, rather than the traditional one-factor-at-a-time (OFAT), which reduces 
experimental trials, time and cost. Screening experiments allow for the development of a broad 
view of the various factors affecting the process, while response surface modeling allows for a 
close up view of areas of interest with the goal of process optimization.  
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Figure 4-10: Schematic diagram of a TEM instrument comprised of 1) an electron gun, 2) electron beam, 3) condenser 
lenses, 4) condenser aperture, 5) sample, 6) objective lens, 7) objective aperture, 8) magnification system and 9) 
fluorescent screen or charge-couple device camera (Adapted from Kuo, 2008). 
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RSM allows for a full quadratic model to be generated with a lower number of 
experimental trials than would usually be required. The most commonly used response surface 
design methods are the Box-Behnken design (BBD) and the Central Composite design (CCD), 
although when these prove insufficient then computer generated designs, referred to as optimal 
designs, may be explored. The CCD consists of a two-level factorial design with center points, as 
well as axial points that provide the additional information needed to determine curvature (Fig. 
4-11). A popular type of CCD is the face centered cubic design (FCC), which has axial points 
that do not extend beyond the area of interest. The distance beyond or within the selected range 
of conditions that axial points extend is determined by the chosen α value, where for an α value 
equal to one the axial points are at the edge of the domain and for an α value greater than one the 
axial points extend beyond the domain. BBDs combine two-level factorial design with an 
incomplete block design with center points. The BBD requires a fewer number of trials than 
CCD; however, this method may produce areas of poor prediction. 
 
 
 
 
 
 
 
For the purposes of this study a full FCC design (α=1) was selected, since it was 
determined that experiments beyond the area of interest, for both chitosan-TPP and chitosan-
carrageenan nanoparticles, would not follow the trends within the area of interest and thus an α 
greater than one would not add any value to the design. The FCC designs created focussed on 
three factors, which resulted in 15 different experimental conditions that were tested in triplicate.     
 
 
 
Figure 4-11: Orientation of points for trial conditions when considering a three factor design  a) Central Composite Design 
b) Face Centered Cubic Design (CCD with α = 1) c) Box-Behnken Design. Black dots represent factorial points, dark blue 
dots center points and light blue dots axial points. 
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4.2.5 Encapsulation of rHu-Erythropoietin 
  Encapsulation involved the mixing of 100µL of 40000IU/mL (~308µg/mL) rHu-EPO 
with 5mL of chitosan solution for 30 minutes before continuing the production process (4.2.1). 
The optimal conditions for chitosan-TPP and chitosan-carrageenan nanoparticle production were 
determined using RSM and chitosan MW studies were conducted under these conditions. The 
chitosan MW studies compared the encapsulation efficiency of low, medium and high MW 
chitosan.  Besides the effect of chitosan MW, the effect of nanoparticle surface charge on the 
encapsulation efficiency of chitosan-TPP and chitosan-carrageenan nanoparticles was also 
analyzed through manipulation of production conditions using RSM. Table 4-4 displays the 
production conditions for each of the trials completed and each trial was performed in triplicate. 
The drug-loaded nanoparticles were centrifuged at 38200rpm (100000 x g) and 4°C in a Sorvall 
Ultra Centrifuge with a Sorvall T-1270 Rotor for 30 minutes. After which the encapsulation 
efficiency was established by measuring the fluorescence of the supernatant (4.2.7). The 
encapsulation efficiency of each trial was calculated using Equation 4-10. 
Equation 4-10 
                          
                                 
                         
       
Table 4-4: Nanoparticle production conditions for encapsulation and controlled release studies. 
Chitosan-TPP Nanoparticles 
Trial CS Concentration 
(mg/mL) 
CS:TPP Mass Ratio Solution pH 
~40mV CS-TPP NPs
i 0.6 4:1 5.2 
~35mV CS-TPP NPs 0.68 3.8:1 5.5 
~30mV CS-TPP NPs 0.65 3.7:1 5.85 
Chitosan-Carrageenan Nanoparticles 
Trial CS Concentration 
(mg/mL) 
CS:CG Mass Ratio Solution pH 
~50mV CS-TPP NPs
i 0.5 3:1 5 
~45mV CS-TPP NPs 0.5 3:1 5.5 
~40mV CS-TPP NPs 0.8 5:1 5.5 
i These conditions represent the optimized conditions as well as the those used during the chitosan MW studies. 
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4.2.6 Controlled Release of rHu-Erythropoietin      
 The drug-loaded nanoparticles from the encapsulation study were re-suspended in 1mL 
of pH 7.4 phosphate buffered saline (PBS) solution and placed in a shaker set at 150rpm and 
37°C. These conditions were selected in order to simulate the stresses that the nanoparticles 
would be subjected to in the human body. Periodically the samples were removed and 
centrifuged at 40000rpm (75000 x g) for 30 minutes in an Optima Max Benchtop with a MLA-
130 rotor. Fresh PBS solution was added, the samples were vortexed for 2 minutes and the 
release study was continued. 
4.2.7 Fluorometer Measurement 
 The rHu-EPO concentration was measured using fluorometric assay, which is based on 
the presence of 3 tryptophan residues present in rHu-EPO that are fluorescent. A Fluorolog3 
instrument was used to measure the fluorescent intensity of the 800µL of sample aliquots. The 
intensity measurements were converted into concentration values through application of a 
standard curve. The excitation wavelength was set to 280nm and the light emission was 
measured over the range of 295-450nm.  
1
2
3
4
5
 
Figure 4-12: Schematic diagram of the Fluorolog3 instrument comprised of 1) a light source, 2) an excitation 
monochromator, 3) a sample compartment, 4) an emission monochromator and 5) a detector (Adapted from Jobin, 2002). 
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When a molecule absorbs light at a certain wavelength and then reacts by emitting light 
at a different wavelength the molecule has fluoresced. This process can be applied for the 
purposes of molecular identification and characterization, and imaging by exciting molecules at 
known excitation wavelengths, and measuring emission wavelengths and intensity. Fluorometry, 
when compared to spectroscopy, provides lower detection limits, since the emission wavelength 
does not have any background interference [84].  
Fluorometers are relatively simple pieces of equipment consisting of a light source, 
monochromator for excitation wavelength selection, a monochromator for emission wavelength 
selection, a detector and analysis computer. The design of the Fluorlog3 is displayed in Figure 4-
12. The Fluorolog3 utilizes a 450W xenon lamp with a spectral range of 200-1000nm for sample 
excitation. The Fluorolog3 used in this study had single-grating monochromators for both 
excitation and emission.  The sample is stored in a T-box compartment and the light emission is 
measured using a PMT detector unit [84, 85]. 
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Chapter 5 
5 Chitosan Nanoparticle Characterization – Screening Process 
As mentioned in the introduction, the chitosan nanoparticle characteristics of interest 
were nanoparticle size, surface charge and size distribution. Particle size is a difficult parameter 
to define for many nanoparticles because the particle geometry may prevent definition of one or 
a few characteristics values, which has led to the use of spherical equivalent diameter.  As 
mentioned previously, the diameters reported are the hydrodynamic diameters equivalent to a 
sphere of the same volume as the particles. The particle size is important to the drug delivery 
system’s ability to penetrate tissue and effectively release the therapeutic agent [86]. Desai et al. 
[31] explored the effect of size on particle uptake in Caco-2 cells, where 100nm nanoparticles 
displayed 2.5 times greater uptake when compared 1µm microparticles and 6 times greater 
uptake than 10µm microparticles. Similar results have been observed in vivo, such as the 
gastrointestinal track of rats where the uptake of nanoparticles was between 15 and 250 times 
greater uptake compared to microparticles and the nanoparticles were able to enter the 
submucosal layers, while microparticles remained trapped in the epithelial lining [87,88].  
When in an aqueous solution, the area around a particle consists of an electrical double 
layer with an outer layer of loosely bound ions (Stern layer) and an inner layer of tightly bound 
ions (HelmHoltz layer). Thus, when a particle moves the ions that are bound tightly enough 
travel with the particle, while those ions outside this boundary, known as the slipping plane, do 
not. The potential difference at this boundary is defined as the zeta potential. Zeta potential is not 
the same as the surface charge of the particle, but is reflective of the particle surface charge. The 
zeta potential is also representative of the colloidal stability. Colloidal systems with zeta 
potentials greater than ±30mV are generally considered stable. By creating nanoparticles of 
various zeta potentials the colloidal stability can be controlled, which dictates the particle 
longevity and could potentially allow for control over the drug release rate. The surface charge is 
also related to the efficiency with which nanoparticles interact with proteins and enzymes within 
bodily fluids. The interaction of nanoparticles with lysozyme and their resultant degradation was 
shown to have a strong dependence on the surface charge [89].  In order, to maintain controlled 
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drug release and avoid being removed from circulation nanoparticles must be able to evade 
lysozomal degradation. Nanoparticle interaction with the surrounding environment is not only 
important for drug delivery efficiency, but also because of the potential health risks. Some 
nanoparticles, such as carbon nanoparticles, have been shown to affect the aggregation of human 
platelets, which can lead to vascular thrombosis. Recent research into the effect of chitosan-
PLGA nanoparticles on platelet aggregation suggests that the application of chitosan 
nanoparticles in concentrations below 10µg/mL does not alter platelet aggregation [90].    
The particle size distribution was investigated through the measurement of the unit less 
parameter polydispersity. Polydispersity is a measure of uniformity with 0 being perfectly 
uniform. When considering colloids a polydipsersity value between 0 and 0.02 is called 
monodisperse and a value between 0.02 and 0.08 is considered a narrow distribution. Uniform 
particle size distribution is important to maintaining a consistent drug release rate and therefore 
should be minimized. Achieving a narrow distribution is challenging and monodisperse 
distributions have only been observed in nature. 
5.1 Screening Characterization of Chitosan-TPP Nanoparticles 
The first step in this study was to determine the effects of chitosan concentration, 
chitosan to TPP mass ratio, solution pH and chitosan MW by performing screening experiments 
to provide an overview of the nanoparticle production process. For each concentration of 
chitosan solution an equal volume TPP solution was added to create final chitosan to TPP mass 
ratios of 3:1, 4:1, 5:1, 6:1 and 7:1; while a pH of 5 was maintained. The chitosan-TPP 
nanoparticle diameter was shown to increase with increasing chitosan concentration and to 
generally increase with an increase in the chitosan-TPP mass ratio for the range of parameters 
tested (Fig. 5-1). The nanoparticle diameter increased in a linear fashion for all chitosan 
concentrations used for mass ratios of 3:1, 4:1 and 5:1 (Fig. A-1); however, for the chitosan 
concentrations of 1.5mg/mL and 2mg/mL the diameter plateaued after these mass ratios. This 
plateau may be the result of decreasing anion concentration, which then neutralizes the anion 
attractive forces halting particle growth. Also, at the higher chitosan to TPP mass ratios of 6:1 
and 7:1, and at certain concentrations large unstable aggregates formed rather than the desired 
nanoparticles.  
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The screening experiments demonstrated that the surface charge decreased in a linear 
manner with an increase in chitosan concentration, while increasing as the chitosan to TPP mass 
ratio rose (Fig. 5-2, Fig. A-2). These trends did not hold for the mass ratios of 6:1 and 7:1 for 
reasons previously stated. The zeta potential measurement was positive for all nanoparticles 
formed, which is to be expected due to the positive charge of chitosan and is consistent with the 
idea that the nanoparticle structure is mostly composed of chitosan. 
 
Figure 5-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle diameter of chitosan-
TPP nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5. 
The particle size distribution also followed a linear increase with an increase in chitosan 
to TPP mass ratio, while polydispersity demonstrated a minimum at a chitosan concentration of 
1.5mg/mL (Fig. 5-3). The nanoparticle size distribution was very broad with polydispersity 
values ranging from approximately 0.24 to 0.38. The broad size distribution could be reflective 
of chitosan’s broad range of MW, since chitosan is sold in low, medium and high MW, each with 
wide distributions. Another option to improve the size distribution profile may be to remove any 
impurities [91]. 
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Figure 5-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential of chitosan-TPP 
nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5. 
 
Figure 5-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity of chitosan-TPP 
nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5. 
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The effect of pH on the nanoparticle characteristics was explored separately at constant 
chitosan concentration and chitosan to TPP mass ratio. The pH levels tested were above 4.5, 
since the isoelectric point of rHu-EPO is ~4.3 and it was necessary to maintain a negative charge 
on the rHu-EPO molecules, in order to maintain the necessary affinity with positively charged 
chitosan later on in the encapsulation and controlled release studies [84]. The pH did not 
demonstrate a simple relationship with either the nanoparticle diameter or the polydipsersity; 
however, both displayed a minimum at the pH of 5.5 (Fig. 5-4A, B). This minimum in particle 
diameter may be observed because of changes to chitosan’s net charge with pH. While the pH is 
shifted from 5.0 to 5.5 chitosan’s positive charge decreases, resulting in less TPP incorporation 
in the particle structure, which causes the particle size to decrease. Whereas, when the pH 
increases from 5.5 to 6.0 further decrease in chitosan’s charge occurs, resulting in reduced 
electrostatic repulsion between chitosan molecules and increased chitosan to TPP binding, again 
causing larger particles to be formed. The relationship between the pH and zeta potential 
appeared to be linear in nature, where a decrease in the zeta potential was observed with an 
increasing solution pH, which resulted due to the chitosan attractive forces weakening as the pH 
approached its isoelectric point of ~6.5. 
The chitosan MW study demonstrated that the MW of chitosan does have an effect on the 
particle diameter with an increase in MW producing an increase in particle diameter when using 
a chitosan to TPP mass ratio of 3:1 or 4:1 (Fig. 5-5A). Beyond the chitosan to TPP mass ratio of 
4:1, the medium MW chitosan generated larger particles than the high MW chitosan, which may 
be the result of the high MW chitosan nanoparticles obtaining their maximum size. The high 
MW chitosan has significantly longer polymer chains and combined with the decreasing amount 
of TPP this means the nanoparticles would no longer have the ionic force required to maintain 
particle size growth beyond a certain diameter. This is re-enforced by the decrease in high MW 
chitosan nanoparticle diameter as the chitosan to TPP mass ratio decreased. The medium MW 
chitosan nanoparticles were able to grow in a manner that allowed for their continued growth 
despite the deceasing amount of TPP. The zeta potential analysis supports the particle diameter 
results because past a chitosan to TPP mass ratio of 4:1 the medium MW chitosan nanoparticles 
have a higher zeta potential than the high MW chitosan nanoparticles (Fig. 5-5B). The plateau in 
high MW chitosan nanoparticle zeta potential demonstrates that no further chitosan was able to 
49 
 
ionotropically gel to the nanoparticles because doing so would have increased the positive zeta 
potential of the nanoparticles. For the most part the medium MW chitosan nanoparticles had a 
greater polydispersity than the low or high MW chitosan nanoparticles, which was expected 
since the medium MW chitosan had a broader range of MW.   
 
Figure 5-4: Effect of pH level on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosan-TPP 
nanoparticles. Medium MW chitosan, chitosan concentration of 1mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C. 
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Figure 5-5: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosan-
TPP nanoparticles. Chitosan concentration of 1mg/mL, pH 5, T= 20±1°C. 
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The goal of the screening process was to generate an overview of the chitosan-TPP 
nanoparticle formation process so that a more focussed analysis and optimization could be 
completed through RSM. The results of the screening process led to the selection of a chitosan 
concentration range between 0.5mg/mL and 1.5mg/mL, and a chitosan to TPP mass ratio range 
of 3:1 to 5:1 for the RSM. The nanoparticles produced within these conditions are between 
100nm and 250nm, which provides the small dimensions desired. The surface charge of the 
nanoparticles within these constraints implies they will be stable and agglomerate free, and also 
allows for further manipulation and the determination of conditions that minimize the 
polydispersity within these parameters.  
5.2 Chitosan-TPP Nanoparticle Morphology 
Assessment of nanoparticle morphology was conducted using transmission electron 
microscopy with the intention of verifying the nanoparticle size and determining shape and 
structure. The first image (Fig. 5-6) captures a single chitosan-TPP nanoparticle produced under 
the same conditions described above, which resulted in a mean particle diameter of ~160nm 
using DLS and is in accordance with the particle size displayed in the image. Previous works 
[64] have reported spheroids; however, imaging results (Fig. 5-6 and 5-7) during this study found 
no one dominant shape, with spheroids being present as well as more elongated structures. Gan 
et al. reported similar results for blank chitosan-TPP nanoparticles, but noted spherical structures 
when BSA was encapsulated within the particle structure. These observations are also in 
agreement with the spherical particles produced after the encapsulation of insulin within 
chitosan-TPP nanoparticles [64] and could mean that the presence of another protein is required 
for generation of a more uniform spherical particle shape.  
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Figure 5-6: TEM image of a chitosan-TPP nanoparticle produced with medium MW chitosan, chitosan concentration of 
1mg/mL, and chitosan to TPP mass ratio of 3:1 at a pH of 5 and T= 20±1°C. 
 
Figure 5-7: TEM image of a group chitosan-TPP nanoparticles produced with medium MW chitosan, chitosan 
concentration of 1mg/mL, and chitosan to TPP mass ratio of 3:1 at a pH of 5 and T= 20±1°C. 
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5.3 Screening Characterization of Chitosan-Carrageenan Nanoparticles 
The study’s initial phase was to broadly investigate the effects of process factors, 
chitosan concentration, chitosan to carrageenan mass ratio and solution pH, on the nanoparticle 
characteristics of interest through a screening process. Chitosan solutions with a concentration 
ranging between 0.125mg/mL and 2mg/mL were added to equal volume carrageenan solutions 
that resulted in the chitosan to carrageenan mass ratios of 2:1, 3:1, 4:1, 5:1 and 6:1, while 
preserving a pH of 5. The chitosan-carrageenan nanoparticle mean diameter ranged between 
~180nm up to ~960nm, with the mean particle diameter increasing with chitosan concentration 
(Fig. 5-8). Also shown in Figure 5-8, the particle diameter decreased as the chitosan to 
carrageenan mass ratio was increased, with the difference being more pronounced at high 
chitosan concentrations. The reduced concentration of carrageenan at the higher mass ratios 
appears to be limiting the nanoparticle size. At the lowest chitosan concentration of 0.125mg/mL 
production of enough nanoparticles to be measurable stopped at a chitosan to carrageenan mass 
ratio of 3:1.  
 
Figure 5-8: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean particle diameter of 
chitosan-carrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.  
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Figure 5-9: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the polydispersity of chitosan-
carrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5. 
The polydispersity of the chitosan-carrageenan nanoparticles ranged between 0.215 and 
0.380. It was shown, for the most part, that the polydispersity decreased with an increased 
chitosan concentration (Fig. 5-9). The exceptions to this pattern were the combination of higher 
chitosan concentrations (1.5mg/mL, 2mg/mL) and low chitosan to carrageenan mass ratios (2:1, 
3:1). This could be due to the manner in which chitosan and carrageenan mix in solution at these 
higher concentrations and viscosities [92]. Also, the polydispersity generally increased with an 
increase in the chitosan to carrageenan mass ratio. 
The surface charge of the nanoparticles ranged between ~42mV and ~51mV for the 
combinations of chitosan concentration and chitosan to carrageenan mass ratio employed. All of 
these were high enough to consider the colloidial systems and the particles within them stable. 
The surface charge readings obtained did not demonstrate any consistent trend in zeta potential 
with chitosan concentration or chitosan to carrageenan mass ratio; however, there was peak zeta 
potential measurement at the chitosan concentration of 0.5mg/mL for almost all the chitosan to 
carrageenan mass ratios tested (Fig. 5-10). 
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Figure 5-10: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta potential of chitosan-
carrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5. 
The solution pH was an important factor since the process was dependent on the ionic 
complexation of oppositely charge compounds whose charge varies with pH. A pH range 
between 4.5 and 6.5 was selected to ensure there would be an affinity between chitosan and rHu-
EPO in the later, encapsulation and controlled release, phase of the study. The isoelectric points 
of rHu-EPO and chitosan are at a pH of ~4.3 and ~6.5 respectively [19, 92]. The nanoparticle 
diameter within the pH range tested showed undulation between minimums and maximums (Fig. 
5-11A). The particle diameter increased towards a solution pH of 6.5 and beyond this point 
aggregation of the nanoparticles occurred. The nanoparticle zeta potential steadily decreased 
with an increasing solution pH demonstrating the reduction in affiliation between chitosan and 
carrageenan as chitosan’s isoelectric point was approached (Fig. 5-11B).  
The chitosan MW study revealed that the MW of chitosan has an effect on the particle 
diameter of chitosan-carrageenan nanoparticles with a substantial difference in particle diameter 
between low and medium MW chitosan nanoparticles. However, there was no major difference 
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between medium and high MW chitosan nanoparticle diameter for the range of conditions tested. 
In Figure 5-12A, it can be seen that the particle diameter decreases for both the low and high 
MW chitosan nanoparticles as the chitosan to carrageenan mass ratio increases, while a plateau is 
reached at a mass ratio of 4:1 for medium MW chitosan. This trend agrees with the earlier results 
for chitosan-carrageenan nanoparticle production and suggests the carrageenan concentration is 
restricting the nanoparticle size. The polydispersity of the nanoparticles increased for all three 
chitosan MWs, but the medium MW chitosan nanoparticles consistently had the greatest 
polydispersity, which is expected since medium MW had the broadest range of MW (Fig. 5-
12B). The zeta potential was lower for the low and high chitosan MW nanoparticles than that of 
the medium MW chitosan nanoparticles, but the same trend was exhibited (Fig. 5-12C).       
 
Figure 5-11: Effect of pH level on A) the mean particle diameter and B) zeta potential of chitosan-carrageenan 
nanoparticles. Medium MW chitosan, chitosan concentration of 0.5mg/mL, chitosan to carrageenan mass ratio of 3:1, 
T=20±1°C. 
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The RSM requires broad knowledge of the production process, so that an area of interest 
can be magnified and further explored, which was achieved through the screening experiments. 
The range of conditions chosen for RSM were a chitosan concentration between 0.5mg/mL and 
1.0mg/mL, a chitosan to carrageenan mass ratio between 3:1 and 5:1, and a solution pH between 
4.5 and 5.5. Within the realm of these conditions the nanoparticle characteristics demonstrated 
distinct patterns that through further analysis could lead to their optimization.  
 
Figure 5-12: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosan-
carrageenan nanoparticles. Chitosan concentration of 0.5mg/mL, pH 5, T= 20±1°C. 
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5.4 Chitosan-Carrageenan Nanoparticle Morphology 
Like for the chitosan-TPP nanoparticles, TEM was performed on the chitosan-
carrageenan nanoparticles in order to substantiate the particle size determined through DLS and 
to provide information on particle shape and structure. Figure 5-13 shows a single chitosan-
carrageenan nanoparticle that under the same production conditions generated particles measured 
to be ~250nm by DLS, which agrees with the results of TEM. A hexagonal structure was present 
in a significant number of the nanoparticles produced and could indicate semi-crystal structure 
and growth after ionic gelation induced nucleation (Fig. 5-13 and 5-14). This style of particle 
formation has been reported before for the similar process of chitosan-TPP nanoparticle 
formation [91], but differs from the results of the only other study on chitosan-carrageenan 
nanoparticles which described the shape as spherical-like [93]. These results could suggest that 
the chitosan-carrageenan nanoparticles initially begin formation in this style and later some 
nanoparticles are caused to deviate from semi-crystal formation or that merely a portion of the 
nanoparticles are produced through this process.  
 
Figure 5-13: TEM image of a chitosan-carrageenan nanoparticle produced with medium MW chitosan, chitosan 
concentration of 0.5mg/mL, and chitosan to carrageenan mass ratio of 4:1 at a pH of 5 and T= 20±1°C. 
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Figure 5-14: TEM image of a group chitosan-carrageenan nanoparticles produced with medium MW chitosan, chitosan 
concentration of 0.5mg/mL, and chitosan to carrageenan mass ratio of 4:1 at a pH of 5 and T= 20±1°C. 
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Chapter 6 
6 Chitosan Nanoparticle Response Surface Modelling 
The purpose of creating the RSMs for particle diameter, zeta potential and polydispersity 
was to establish a method for the accurate modulation of these nanoparticle characteristics during 
the production process. Theoretically the ideal nanoparticles for drug delivery would have the 
smallest size, highest surface charge and lowest polydispersity possible; however, depending on 
the release mechanism of the drug other combinations of nanoparticle size and surface charge 
may be optimal. These models should allow for the production of nanoparticles with specific 
responses, so that in turn the response affects on encapsulation and controlled release can be 
determined.  
The CCD method was chosen since performing the multiple experimental production 
runs required was not a limiting factor and the additional accuracy this method provided was 
desired. In addition, a FCC design was also used since the area outside of the designated range of 
process conditions did not display the same relationships as those within. The data was analyzed 
using RSM software for fit of linear, two-factor interaction terms (2FI) and quadratic models 
between the design factors and the responses.  
The coefficient of determination (R
2
) is often used as the benchmark for model fit, but 
unfortunately it is biased, since simply increasing the order of regression can only increase R
2
, 
especially when using small sample sizes. R
2
 measures the amount of variation relative to the 
mean, which is determined using the sum of the squares relative to zero (SSModel) and sum of 
squares relative to the mean (SSCorTotal), as seen in Equation 6-1.  The PRESS (predicted residual 
sum of squares) and R
2
Pred (R
2
 predicted) provide additional information on model fit that cannot 
be ignored. PRESS is ascertained by summing the square of the residuals (ei) between the 
individual observations and the prediction from the regression model generated without 
observation i (Eq. 6-2). The goal is to create a regression model that minimizes the PRESS. 
R
2
Pred is another form of the PRESS, but in a value that is similar to the coefficient of 
determination (Eq. 6-3). Unlike the R
2
, which generally ranges between 0 and 1, R
2
Pred frequently 
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has negative values meaning that the mean value is a better fit than the regression model. 
Another value of interest is the adjusted R
2
 (R
2
Adj), which provides a less biased measure of fit 
than R
2
 by penalizing model parameters, so that only a substantial improvement in fit will 
increase the R
2
Adj value. In Equation 6-4, n represents the number of samples and p represents 
the number of parameters in the regression model. All of the mentioned statistical devices were 
used when determining the appropriate model for each process factor.       
Equation 6-1 
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6.1 Chitosan-TPP Nanoparticle RSM 
The linear and 2FI models for particle diameter both fit reasonably well based on the R
2
, 
R
2
Pred, R
2
Adj values; however, the quadratic model was able to significantly lower the PRESS and 
provide a slight improvement in the R
2
, R
2
Pred, R
2
Adj values (Table 6-1). When evaluating the 
RSM for zeta potential the quadratic model again was determined to be the best fit due to the 
minimization of PRESS. The polydispersity response surface model selection was the most 
obvious with the quadratic model providing significant improvements over the other two models 
in every category. All three RSMs were plagued by poor results on the lack of fit test, where 
significant lack of fit was calculated. This can be a common problem when applying RSM to 
laboratory studies because the conditions are under strict control, especially for small scale 
research, the pure error may be underestimated leading to a biased lack-of-fit test [83]. In these 
situations when all other model statistics and diagnostics are fine the model should be accurate. 
However, to ensure RSM accuracy trials within the model range, but not included in model 
development, were compared to values predicted by the RSMs and were found to be sufficiently 
62 
 
accurate. The RSMs developed for particle diameter, zeta potential and polydispersity are 
displayed below (Equations 6-5, 6, 7), as well as the units for each term contained within the 
equations. 
Table 6-1: Chitosan-TPP nanoparticle RSM fit characteristics. 
Response Relation R
2
 (%) R
2
Pred (%) R
2
Adj (%) PRESS 
Particle Diameter Linear 90.68 88.68 90.04 8507.23 
 2FI 94.91 93.62 94.17 4795.73 
 Quadratic 97.50 96.04 96.91 2978.45 
Zeta Potential Linear 84.13 79.98 83.04 234.57 
 2FI 95.73 94.33 95.11 66.49 
 Quadratic 97.56 96.03 96.98 46.53 
Polydispersity Linear 33.51 23.06 28.98 0.0981 
 2FI 36.07 16.92 26.71 0.1060 
 Quadratic 92.46 87.88 90.67 0.0155 
Equation 6-5 
                                                              
                                         
Equation 6-6 
                                                            
                                  
Equation 6-7 
                                                              
                                          
 
X = Chitosan Concentration (mg/mL) Y = Chitosan:TPP Mass Ratio 
Z = Solution pH 
The RSM for particle diameter displayed the least amount of curvature of the three 
responses; however, the majority of the curvature that was present in the quadratic relationship is 
due to the chitosan to TPP mass ratio (Fig. 6-1). The earlier results demonstrating a drop in 
particle diameter around a pH of 5.5 were supported by RSM where the model indicated that the 
minimum particle diameter of ~98nm would be achieved with a chitosan concentration of 
0.5mg/mL, chitosan-TPP mass ratio of 3 and a pH 5.44.  
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The RSM generated for colloidal polydispersity exhibits consistent shape throughout the 
various solution pH levels and the relationships with chitosan concentration and chitosan-TPP 
mass ratio determined by the screening process are predicted as well (Fig. 6-3). The colour 
mapping on the surface and contour plots shows that polydispersity has a minimum based on pH, 
which the model determined was ~0.16 and would be achieved with a chitosan concentration of 
1mg/mL, chitosan-TPP mass ratio of 3:1 and a pH of 5.5. 
The RSM for zeta potential expressed a significant amount of curvature with the overall 
shape of the response surface changing with the solution pH (Fig. 6-2) and with the 3D surface 
plots at the model limits of pH 5 and pH 6 almost resembling mirror images. As the colour 
mapping indicates, the zeta potential does indeed decrease with an increase in solution pH, but 
the relationship between zeta potential positively correlates with the chitosan concentration.  
 
Figure 6-1: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and 
chitosan to TPP mass ratio with the mean particle diameter of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 
and 6.0. Medium MW chitosan, T= 20±1°C.  
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Figure 6-2: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and 
chitosan to TPP mass ratio with the zeta potential of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 and 6.0. 
Medium MW chitosan, T= 20±1°C.  
 
Figure 6-3: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and 
chitosan to TPP mass ratio with the polydispersity of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 and 6.0. 
Medium MW chitosan, T= 20±1°C. 
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6.2 Chitosan-Carrageenan Nanoparticle RSM 
All three models, linear, 2FI and quadratic, fit the particle diameter data well based on the 
R
2
, R
2
Pred, R
2
Adj values (Table 6-2). The PRESS was lower when applying the linear model, 
which was one of the reasons for its selection as the model of choice. The principle of parsimony 
was the other reason, this principle suggests selecting the simplest of scientific explanations 
when selecting between equally accurate solutions. The RSM for zeta potential yielded the 
quadratic model the clear cut favourite, since R
2
, R
2
Pred, R
2
Adj values were significantly higher for 
this model and the PRESS was minimized. The polydispersity response surface model selection 
was between the 2FI and quadratic models, which both had almost identical values, so again the 
decision was based on the principle of parsimony to select the 2FI model. Like the results for the 
chitosan-TPP nanoparticles, the RSMs for chitosan-carrageenan nanoparticles for particle 
diameter and zeta potential exhibited poor lack of fit, but the polydispersity RSM showed no 
significant lack of fit. Again, trials within the model range, but not included in model 
development, were compared to values predicted by the RSMs and were determined to be 
accurate. The RSM for polydispersity had the weakest fit, despite passing the lack-of-fit test, but 
was able to provide some guidance as to the potential polydispersity of the samples. However, 
due to the lower fit of the model less emphasis was placed on the polydispersity RSM when 
optimization of nanoparticle production was performed. The RSMs developed for particle 
diameter, zeta potential and polydispersity are displayed below (Equations 6-8, 9, 10), as well as 
the units for each term contained within the equations. 
Table 6-2: Chitosan-carrageenan nanoparticle RSM fit characteristics. 
Response Relation R
2
 (%) R
2
Pred (%) R
2
Adj (%) PRESS 
Particle Diameter Linear 95.16 94.36 95.16 4810.03 
 2FI 95.22 93.89 94.46 5212.28 
 Quadratic 95.47 92.79 94.31 6149.53 
Zeta Potential Linear 76.79 72.34 75.09 199.33 
 2FI 79.42 72.55 76.16 197.78 
 Quadratic 86.80 79.44 83.40 148.14 
Polydispersity Linear 63.78 54.02 61.13 0.025 
 2FI 77.50 63.83 73.95 0.020 
 Quadratic 78.79 62.38 73.34 0.020 
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Equation 6-8 
                                                   
Equation 6-9 
                                                               
                               
Equation 6-10 
                                                           
                    
X = Chitosan Concentration (mg/mL) Y = Chitosan:Carrageenan Mass Ratio 
Z = Solution pH 
The linear RSM developed for particle diameter displayed minimum values when the 
chitosan concentration was at its lowest and chitosan-carrageenan mass ratio was at its highest 
(Fig. 6-4). This result agrees with the data from the screening process (5.3); however, no 
minimum was described at the pH of 5 showing that pH has no significant effect within this 
range of production conditions. The minimum particle diameter within the range of conditions 
tested was determined to be ~260nm and would be achieved with a chitosan concentration of 
0.5mg/mL, chitosan-carrageenan mass ratio of 5 and a pH of 5.  
The RSM for particle size distribution (polydispersity) did not indicate a significant 
relationship with solution pH, as was determined in the screening process, with no considerable 
increase or decrease in polydispersity and consistent 3D model shape. However, the relationships 
between polydispersity, and chitosan concentration and chitosan-carrageenan mass ratio 
displayed are in agreement with those determined in the screening process (Fig. 6-5). As the 
selection of the 2FI model implies there was some curvature to the model, which occurred in 
both the chitosan concentration and chitosan-carrageenan mass ratio axes. 
The zeta potential RSM displayed considerable curvature with the general shape of the 
response surface remaining mostly the same with changing solution pH (Fig.6-6). The contour 
mapping and 3D models indicate the screening result were accurate in that the zeta potential does 
in fact decrease with an increase in solution pH. The RSM also confirmed that decreasing the 
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chitosan concentration within these conditions increases the zeta potential. The bulk of the 
curvature appears to be due to the chitosan-carrageenan mass ratio, which is also somewhat 
shown in Figure 5-10.   
 
Figure 6-4: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and 
chitosan to carrageenan mass ratio with mean particle diameter of chitosan-carrageenan nanoparticles for the pH values 
of 4.5, 5.0 and 5.5. Medium MW chitosan, T=20±1°C. 
 
Figure 6-5:  A) Response surface 3D model and B) contour plot of the relationship between chitosan concentration and 
chitosan to carrageenan mass ratio with the polydispersity of chitosan-carrageenan nanoparticles. Medium MW chitosan, 
pH 5, T=20±1°C. 
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Figure 6-6: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and 
chitosan to carrageenan mass ratio with the zeta potential of chitosan-carrageenan nanoparticles for the pH values 4.5, 
5.0 and 5.5. Medium MW chitosan, T=20±1°C.  
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Chapter 7 
7 Encapsulation and Controlled Release of rHu-EPO 
The encapsulation was performed, as described in Chapter 3 (Materials and Methods), by 
the addition of 100µL of rHu-EPO into the chitosan solution during the nanoparticle production 
process. The RSMs were used to determine the optimal conditions for nanoparticle formation 
with small diameter, high surface charge and low polydispersity being the targets. The goal was 
to strike a balance between these characteristics by producing the overall optimal particle; 
however, somewhat more importance was placed on surface charge. The encapsulation and 
controlled release of rHu-EPO from chitosan-TPP nanoparticles had previously been explored by 
Bokharaei et al [92]; however, not in as much depth. The application of chitosan-carrageenan 
nanoparticles as means of encapsulation and controlled release for rHu-EPO was a novel method 
that had not been investigated.  
Zeta potential was isolated as the most important factor, due to its significance to colloid 
stability, and a study altering particle zeta potential was performed for both types of 
nanoparticles with the hope that manipulating the zeta potential would allow for a method of 
controlling the drug release rate. The effects of particle diameter and polydispersity could have 
also been examined, but their influence on drug release, especially particle diameter, has a more 
vital impact through the bodily nanoparticle clearance rate. This makes an investigation of the 
effects of particle diameter and polydispersity better suited for an in vivo study, which is beyond 
the scope of this research. 
Chitosan MW has previously been reported to have affects on both the encapsulation and 
drug release rate from chitosan microparticles. In a study by Genta et al., chitosan microspheres 
generated through a modified dry-in-oil emulsion method demonstrated improved encapsulation 
efficiency of ketoprofen when a mixture of high/low MW chitosan (2:1 w/w) was applied [94]. 
The drug release rate of ketoprofen and oxytetracycline from chitosan microspheres has been 
reported to decrease with an increase in chitosan MW [94, 95]. When considering chitosan 
nanoparticles the relationship between encapsulation efficiency and chitosan MW has not been 
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as clear with reports that efficiency increases with increased chitosan MW and reports suggesting 
the opposite relationship [96]. The relationship between chitosan MW and bovine serum albumin 
release has previously been studied with results suggesting that increasing the chitosan MW 
leads to a reduced protein release rate, which may be the result of reduced particle swelling with 
increased chitosan MW and or the potential for the protein to bond at multiple sites [96].           
7.2 Chitosan-TPP – Encapsulation and Controlled Release 
When trying to balance different nanoparticle characteristics, but with a slightly higher 
importance placed on surface charge, the RSMs yielded a chitosan concentration of 0.6mg/mL, 
CS:TPP mass ratio of 4:1 and a pH level of 5.2 as the optimal conditions. According to the 
model and confirmed by DLS and LDE, under these conditions a nanoparticle diameter of 
~138nm, zeta potential of ~40mV and a polydispersity of ~0.275 can be achieved. The optimized 
conditions yielded an encapsulation efficiency of 43.45±0.84% (Table 7-1), which is greater than 
the 34.5% previously achieved using chitosan-TPP nanoparticles [92].  
Table 7-1: rHu-EPO encapsulation results within chitosan-TPP. 
Trial Encapsulation 
Mass Encapsulated (µg) Encapsulation Efficiency (%) 
Low MW CS 11.98±0.14 38.93±1.48 
Medium MW CS
i 13.37±0.08 43.45±0.84 
High MW CS 14.07±0.06 45.71±0.63 
~35mV - CS-TPP NPs 12.21±0.12 39.70±0.63 
~30mV - CS-TPP NPs 10.80±0.06 35.11±1.23 
i 
The chitosan-TPP nanoparticles made with medium MW chitosan had a zeta potential of ~40mV. 
A comparison of the effect of chitosan molecular weight on encapsulation and controlled 
release of rHu-EPO was performed by using the above conditions with low and high MW 
chitosan, in addition to the previously tested medium MW chitosan. As seen in Table 7-1, the 
encapsulation efficiency increased when using high as compared to low MW chitosan possibly 
due to an increase in the porosity of the nanoparticles, since the increase in the length of the 
polymer chains should produce particles that are more porous. Another potential explanation is 
that the structural formation of higher MW chitosan allows for more hydrogen bonding sites and 
thus greater drug encapsulation [96]. The manipulation of the nanoparticle surface charge using 
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the RSMs developed here and its effects on the encapsulation and controlled release of rHu-EPO 
was another area of interest. The results showed that as surface charge increased so did the 
encapsulation efficiency (Table 7-1). 
 The particle diameter and zeta potential of chitosan-TPP nanoparticles, produced under 
the conditions suggested by optimization using the RSMs, were tested for both blank and rHu-
EPO loaded nanoparticles. The blank nanoparticle measurements showed a high degree of 
agreement between the actual particle characteristics and those predicted by the RSMs, helping 
prove their validity. The average difference between the particle diameter of blank and rHu-EPO 
loaded nanoparticles was ~16nm and the average difference in zeta potential was ~8mV. The 
addition of rHu-EPO was shown to increase the particle diameter, while decreasing the particle 
zeta potential (Table 7-2).  The decrease in the zeta potential appeared to be related to the 
chitosan MW, with an increase in MW producing a larger decrease in zeta potential. This effect 
could be connected to the encapsulation efficiency since increased chitosan MW led to increased 
encapsulation of rHu-EPO, which would correspond to the greater drop in particle zeta potential 
due to rHu-EPO’s negative charge. The results also implied that the lower the zeta potential 
without the presence of rHu-EPO the larger the decrease in zeta potential when rHu-EPO is 
encapsulated.  
Table 7-2: Comparison of particle diameter and zeta potential between blank and EPO loaded chitosan-TPP 
nanoparticles. 
Trial 
Particle Diameter (nm) Zeta Potential (mV) 
RSM 
Prediction 
Blank NPs EPO- NPs RSM 
Prediction 
Blank NPs EPO- NPs 
LMW CS ~ 82.4±2.7 101.3±2.1 ~ 36.45±1.77 30.37±3.25 
MMW CSi 138.2 140.3±2.5 155.6±1.7 39.7 39.18±1.61 31.82±3.20 
HMW CS ~ 148.4±2.3 169.5±1.8 ~ 38.31±1.86 29.86±1.09 
~35mV 
CS-TPP NPs 
138.6 136.5±1.9 148.1±2.9 35 35.95±2.24 27.59±1.56 
~30mV 
CS-TPP NPs 
143.7 140.2±2.4 153.1±2.1 30 29.15±1.97 19.58±1.80 
i 
The chitosan-TPP nanoparticles made with medium MW chitosan had a zeta potential of ~40mV. 
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Figure 7-1: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles produced using low, 
medium and high MW chitosan. [CS] = 0.6mg/mL, CS:TPP = 4:1, pH 5.2 and T= 20±1°C. 
The optimized chitosan-TPP nanoparticles made with medium MW chitosan released 
~30% percent of the encapsulated rHu-EPO in the first 24 hours, ~52% within the first week and 
~68% within a two week period. These values are within the range of those previously reported 
for biodegradable nano and microparticles, which ranged between 30-40% released within the 
first 48 hours and between 60-80% released over a two week period [9,92].  
When comparing the release of rHu-EPO from chitosan-TPP nanoparticles composed 
with low, medium and high MW chitosan (Fig. 7-1) it can been seen that the rate of release 
decreases with an increase in the chitosan MW. This is the opposite of the increase in 
encapsulation efficiency with chitosan MW trend reported. The decrease in rate of release may 
be due to a combination of reduced nanoparticle swelling with a higher chitosan MW and the 
possibility of multiple bonding sites between rHu-EPO and chitosan [96]. The initial drug release 
burst observed for most nanoparticles is due to the drug adsorbed to the particle surface and the 
drug absorbed within the outer most layer of the particle matrix [2]. The surface charge study 
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(Fig. 7-2) demonstrated that as the zeta potential of the particles was increased from 30mV to 
40mV the rate of release decreased. This data demonstrates clearly that altering the particle 
surface charge, thus particle stability, can change the release characteristics. The nanoparticles 
with surface charges of ~35mV and ~40mV were able to provide a steadier rate of release, where 
as the ~30mV nanoparticles released the majority of the encapsulated drug within 3-4 days, after 
which the release rate declined demonstrated by a decrease in separation between the percent 
release of the ~30mV and ~35mV nanoparticles (More clearly displayed in Figure C-4,  
Appendix C). 
 
Figure 7-2: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles with surface charges of 
~30mV, ~35mV and ~40mV. Medium MW chitosan, T= 20±1°C. 
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7.3 Chitosan-Carrageenan – Encapsulation and Controlled Release 
The optimized process conditions determined using the RSMs were a chitosan 
concentration of 0.5mg/mL, a chitosan to carrageenan mass ratio of 3:1 and a pH of 5. RSM 
predicted under these conditions a nanoparticle diameter of ~310nm, zeta potential of ~50mV 
and a polydispersity of ~0.235 could be achieved and was confirmed by DLS and LDE (Table 7-
4). Similar chitosan-TPP nanoparticles were investigated as an encapsulation and controlled 
release mechanism for rHu-EPO and yielded an encapsulation efficiency of 34.5% [92], which is 
considerably lower than the 47.97±4.10% obtained by this study’s chitosan-carrageenan 
nanoparticles.  
Table 7-3: rHu-EPO encapsulation results within chitosan-carrageenan. 
Trial 
Encapsulation 
Mass Encapsulated (µg) Encapsulation Efficiency (%) 
Low MW CS 13.65±0.32 44.36±3.40 
Medium MW CS
i 14.76±0.58 47.97±4.10 
High MW CS 15.58±0.20 50.13±2.11 
~45mV - CS-CG NPs 13.77±0.05 44.74±0.51 
~40mV - CS-CG NPs 13.01±0.21 42.28±2.17 
i 
These chitosan-carrageenan nanoparticles doubled as the ~50mV nanoparticles. 
Under the RSM optimized conditions, the particle diameter and zeta potential of 
chitosan-carrageenan nanoparticles were tested for both blank and rHu-EPO loaded 
nanoparticles. The validity of the RSMs developed was furthered during this study since the 
blank nanoparticle measurements demonstrated consistency between the actual particle 
characteristics and those predicted by the RSMs. The average difference between the particle 
diameter of blank and rHu-EPO loaded nanoparticles was ~19.5nm and the average difference in 
zeta potential was ~7.5mV. Overall the addition of rHu-EPO was revealed to increase the 
particle diameter and decrease the particle zeta potential (Table 7-4).  Similar to the results for 
chitosan-TPP nanoparticles, as the chitosan MW increased so did the drop in zeta potential when 
rHu-EPO was added. Furthering the theory that the effect may be associated with encapsulation 
efficiency since, again for chitosan-carrageenan nanoparticles, increasing chitosan MW led to 
greater rHu-EPO encapsulation. Unlike the chitosan-TPP nanoparticles, the results did not imply 
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that the lower the zeta potential without rHu-EPO incorporated the larger the drop in zeta 
potential when rHu-EPO is encapsulated. The chitosan-carrageenan nanoparticles displayed a 
trend of increasing difference in particle size between blank and rHu-EPO loaded nanoparticles 
with increased chitosan MW and decreased initial particle zeta potential. These trends could be 
explained using the same theories as before where the increase in rHu-EPO encapsulation, thus 
the amount of rHu-EPO within the structure and on the particle surface, resulted in a greater 
particle diameter and the decrease in initial particle zeta potential meant a more rapid 
destabilization of the nanoparticles when rHu-EPO was included.  
Table 7-4: Comparison of particle diameter and zeta potential between blank and EPO loaded chitosan-carrageenan 
nanoparticles. 
Trial 
Particle Diameter (nm) Zeta Potential (mV) 
RSM 
Prediction 
Blank NPs EPO- NPs RSM 
Prediction 
Blank NPs EPO- NPs 
LMW CS ~ 221.8±2.7 235.4±1.3 ~ 48.44±1.33 43.86±1.51 
MMW CS
i 311.0 305.9±2.8 322.2±4.3 50 48.89±0.94 42.22±2.38 
HMW CS ~ 307.1±3.3 334.7±3.7 ~ 47.37±0.62 37.43±0.96 
~45mV 
CS-CG NPs 
309.1 316.1±2.4 334.2±3.6 45 44.74±0.73 35.60±2.84 
~40mV 
CS-CG NPs 
316.2 318.8±3.1 340.0±4.1 40 40.82±0.67 33.75±1.43 
i 
These chitosan-carrageenan nanoparticles doubled as the ~50mV nanoparticles. 
The effect of chitosan MW on the encapsulation and controlled release of rHu-EPO was 
studied using three commercially available grades of chitosan (low, medium and high MW). 
During this comparison all conditions were maintained at the optimum settings determined by 
the RSMs and only the grade of chitosan was altered. It was found that as the MW of chitosan 
was increased the encapsulation efficiency rose (Table 7-3), potentially due to an increase in the 
nanoparticle porosity and changes in the sterical arrangement of the polymer chain, which may 
allow for a greater number of hydrogen bonding sites between chitosan and the therapeutic agent 
[96].  Another comparison was the effect of surface charge on encapsulation and controlled 
release, which utilized the RSMs developed to manipulate the nanoparticle zeta potential. As the 
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zeta potential increased from 40mV to 50mV the encapsulation efficiency of the chitosan-
carrageenan nanoparticles also increased. 
The optimized chitosan-carrageenan nanoparticles (medium MW chitosan) in the first 48 
hours released ~32% percent of the encapsulated rHu-EPO, in the first week ~42% and in a two 
week time-span ~50%. When compared to other nano/microparticle rHu-EPO delivery systems 
this rate of release is within the 30-40% range reported for the first 48 hours and is less than the 
60-80% rate of release obtained during a period of two weeks [9, 92].  
 
Figure 7-3: Comparison of rHu-EPO percent release over time for chitosan-carrageenan nanoparticles produced using 
low, medium and high MW chitosan. [CS] = 0.5mg/mL, CS:CG = 3:1, 5.0 pH and T= 20±1°C. 
For all of the trials conducted, the bulk of the drug release occurred within the initial 24 
hours and is most likely due to a large amount of rHu-EPO adsorbed to the particle surface [5]. 
Altering the chitosan MW from low to high decreased the amount of rHu-EPO released, with the 
main difference in release rate being within the first 12 hours (Fig. 7-3). The decrease in rHu-
EPO release rate, as mentioned earlier, may be due to an increase in the number of bonding sites, 
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which could lead to multiple bonds between chitosan and rHu-EPO reducing the rate of release. 
Also, mentioned previously, the nanoparticle swelling decreases with an increase in chitosan 
MW, which could contribute to a decreased release rate. The manipulation of nanoparticle zeta 
potential between 50mV and 40mV demonstrated that decreasing the surface charge leads to 
increased rHu-EPO release, evidence that manipulation of the nanoparticle surface charge can 
allow for control over the drug release rate (Fig. 7-4).     
 
Figure 7-4: Comparison of rHu-EPO percent release over time for chitosan-carrageenan nanoparticles with surface 
charges of ~40mV, ~45mV and ~50mV. Medium MW chitosan, T= 20±1°C. 
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Chapter 8 
8 Conclusions and Recommendations 
8.1 Conclusions 
Chitosan-TPP and chitosan-carrageenan nanoparticles were generated through ionotropic 
gelation using flush mixing under a variety of conditions to evaluate the effects of chitosan 
concentration, chitosan to anion mass ratio and solution pH on the nanoparticle characteristics. 
The resulting chitosan-TPP nanoparticles had particle diameters ranging between 100 and 
400nm, surface charges between 30 and 50mV, and particle size distributions ranging between 
0.2 and 0.4. While, the chitosan-carrageenan nanoparticles displayed particle diameters between 
200 and 1000nm, surfaces charges between 40 and 55mV, and particle size distributions between 
0.2 and 0.35.  Both types of chitosan nanoparticles grew in size with an increase in chitosan 
concentration; however, raising the chitosan to anion mass ratio caused the chitosan-TPP 
nanoparticles to increase in diameter, while causing the chitosan-carrageenan nanoparticles to 
decrease in diameter. Direct trends were identified between the chitosan concentration and 
chitosan to anion mass ratio to zeta potential for chitosan-TPP nanoparticles, while chitosan-
carrageenan nanoparticles were shown to have a peak zeta potential at a chitosan concentration 
of 0.5mg/mL, but demonstrated no other trends.  The other important factor studied in the 
screening process, polydispersity, was determined to increase with an increase in chitosan to 
anion mass ratios for both types of chitosan nanoparticles. Investigation into the particle 
morphology revealed that both chitosan-TPP and chitosan-carrageenan nanoparticles had no 
prominent shape, such as a spherical shape. The chitosan-carrageenan morphology did reveal 
that a significant amount of these nanoparticles had a hexagonal structure that could indicate 
semi-crystal structure and growth after ionic gelation induced nucleation. The study on the effect 
of pH on chitosan nanoparticle formation found that the zeta potential decreased with increasing 
pH for both types of nanoparticles, as well as determined that particle diameter and 
polydispersity for chitosan-TPP nanoparticles could be minimized at a solution pH of 5.5. The 
exploration into the effect of chitosan MW on nanoparticle formation established that the larger 
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the MW the larger the particle diameter; however, nanoparticles produced using medium MW 
chitosan yielded both higher zeta potential and polydispersity.  
From this screening process a more narrow range of conditions were selected to be 
further investigated using the response surface methodology in hopes of creating a more accurate 
method of controlling the nanoparticle characteristics. Accurate quadratic RSMs were generated 
for the chitosan-TPP nanoparticles and their three target characteristics that could be used to 
minimize particle size to as little as 98nm and polydispersity to as low as 0.16, and maximize 
zeta potential to ~45mV. RSMs were also successfully generated for the chitosan-carrageenan 
nanoparticle characteristics of particle diameter, zeta potential and polydispersity by linear, 
quadratic and 2FI RSMs, respectively. Through manipulation of the process conditions using 
these RSMs the chitosan-carrageenan nanoparticle diameter and polydispersity could be 
minimized to ~260nm and ~0.16, while producing particle zeta potential as high as ~52.5mV is 
possible. Optimized nanoparticles were produced by balancing the different particle 
characteristics’ targets, with slightly more emphasis applied to surface charge.  The RSMs 
yielded a chitosan concentration of 0.6mg/mL, chitosan to TPP mass ratio of 4:1 and a pH level 
of 5.2 as the optimal conditions for chitosan-TPP nanoparticle production. While, the optimized 
process conditions determined using the RSMs for chitosan-carrageenan nanoparticles were a 
chitosan concentration of 0.5mg/mL, a chitosan to carrageenan mass ratio of 3:1 and a pH of 5.   
The optimized chitosan-TPP nanoparticles resulted in an encapsulation efficiency of 
43.45±0.84% and released ~30% of the encapsulated rHu-EPO in 24 hours and ~68% within a 
two week period. While, the optimized chitosan-carrageenan nanoparticles yielded an 
encapsulation efficiency of 47.97±4.10% and  released ~32% of the encapsulated rHu-EPO in 48 
hours and ~50% within a two week period. Both of the encapsulation results, for the two 
different chitosan nanoparticles, are an improvement over the previously reported encapsulation 
efficiency of 34.5% [91]. The RSMs were also used to determine the effect of surface charge on 
rHu-EPO encapsulation and release rate, and demonstrated that increasing the surface charge 
increases the encapsulation efficiency and produces a more stable drug release, which were 
trends seen in both types of chitosan nanoparticles. The surface charge study also showed that 
through manipulation of the zeta potential nanoparticles that release a therapeutic agent within a 
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certain desired timeframe can potentially be produced. The effect of chitosan molecular weight 
on encapsulation and controlled release was determined through experimentation using low, 
medium and high MW commercial grade chitosan and established that increasing the MW 
improved the encapsulation efficiency and decreased the rHu-EPO rate of release from both 
chitosan nanoparticles. The results of this research demonstrate the potential for chitosan 
nanoparticles as a drug delivery system for rHu-EPO and other therapeutic agents, and the 
importance of manipulating process conditions to achieve optimum results. 
8.2 Recommendations 
 When comparing the chitosan-TPP and chitosan-carrageenan nanoparticles the results of 
this work have shown that chitosan-TPP nanoparticles can be produced that have half the particle 
diameter of that of the smallest chitosan-carrageenan nanoparticles generated. The difference in 
particle size can be attributed to the difference in polymer length between TPP and the longer 
carrageenan polymer. The chitosan-carrageenan nanoparticles over all had a greater zeta 
potential than that of the chitosan-TPP nanoparticles, which later manifested itself in the 
encapsulation and controlled release of rHu-EPO where the chitosan-carrageenan nanoparticles 
outperformed the chitosan-TPP nanoparticles in both the encapsulation and controlled release. 
Based on the results the chitosan-carrageenan nanoparticles appear to be a better drug delivery 
mechanism for the encapsulation and controlled release rHu-EPO than chitosan-TPP 
nanoparticles. However, the application of rHu-EPO must be taken into account since more 
importance on particle diameter may mean that chitosan-TPP nanoparticles are more suited for 
certain applications. 
 One of the more novel applications of rHu-EPO and potential use for rHu-EPO loaded 
chitosan nanoparticles pertains to the compound’s tissue protective properties and their ability to 
help patients recover after acute myocardial infarction (MI) [12, 97]. When developing a drug 
delivery system for the application of rHu-EPO in treatment of MI the nanoparticle system could 
be inserted onto the tissue at the site of treatment rather than intravenous injection. For such an 
application the importance of particle size would be diminished, since the size constraints 
associated with particles in circulation would be removed. Chitosan-carrageenan particles would 
be the more ideal of the two types of chitosan nanoparticles created in this study for application 
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in MI treatment, due its increased encapsulation and prolonged release of rHu-EPO, as well as 
the removal of size limitations. The use of high MW chitosan would also increase encapsulation 
and provide a longer more sustained release. 
 The chitosan-carrageenan nanoparticles did demonstrate a marked improved in 
encapsulation and controlled release of rHu-EPO; however, the initial drug burst was still 
witnessed and is an obstacle to maintaining a consistent and prolonged release. In order to get a 
more consistent release mechanism the use of a cross-linker may be investigated, but as 
discussed in Chapter 3 this is less than ideal due to the potentially harmful production conditions. 
Chitosan-TPP nanoparticles coated with alginate were reported to have a significantly reduced 
burst effect when releasing BSA [98]; thus, adding an outer layer, whether alginate or another 
polyanion, could provide the extra resistance needed to prevent the initial rHu-EPO burst. 
Further studies into the effect of nanoparticle structure on the biological activity of rHu-EPO and 
in vivo release studies need to be performed in order determine the true potential of chitosan 
nanoparticles for rHu-EPO encapsulation and controlled release.                       
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Appendices 
A. Screening Process 
Table A-1: Chitosan-TPP nanoparticle diameter characterization. Medium MW chitosan, pH 5 and T=20±1°C. 
CS-TPP  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.5mg/mL 
3:1 110.5000 106.7±0.9 103.2±1.3 106.8±1.3 
4:1 128.8000 125.1±1.9 125.9±2.9 126.6±2.2 
5:1 142.9000 138.1±2.1 139.7±3.5 140.2±3.0 
6:1 165.5000 165.7±5.7 170.2±3.7 167.1±5.7 
7:1 Unstable Unstable Unstable Unstable 
Chitosan Concentration = 1.0mg/mL 
3:1 164.4±1.0 158.9±1.8 155.7±1.3 159.7±1.4 
4:1 184.0±1.9 184.6±2.2 181.4±1.3 183.3±1.8 
5:1 207.3±0.4 209.2±1.9 208.2±2.5 208.2±1.8 
6:1 230.6±2.9 230.9±2.9 232.1±3.3 231.2±3.0 
7:1 259.4±3.7 251.2±4.1 263.1±1.4 257.9±3.3 
Chitosan Concentration = 1.5mg/mL 
3:1 227.3±1.6 223.5±1.5 220.31.2 223.7±1.4 
4:1 235.1±2.0 235.6±2.0 234.4±1.9 235.0±2.0 
5:1 243.3±2.0 243.0±1.5 245.0±4.3 243.8±2.9 
6:1 241.2±1.6 242.8±3.2 238.7±2.2 242.9±2.6 
7:1 241.3±2.5 241.0±1.3 244.7±2.7 240.3±2.1 
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Table A-1 Continued 
CS-TPP  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 2.0mg/mL 
3:1 289.8±4.9 284.7±2.2 292.3±4.8 288.9±4.2 
4:1 301.4±4.5 299.3±3.7 301.5±2.2 297.7±3.6 
5:1 313.1±2.1 313.9±4.2 312.7±3.4 313.2±3.3 
6:1 313.7±4.6 313.9±3.5 312.2±4.2 313.3±4.1 
7:1 306.8±3.5 307.6±4.6 304.2±3.5 306.2±3.9 
 
Chitosan Concentration = 3.0mg/mL 
3:1 348.4±3.0 355.6±2.7 353.8±3.0 352.6±2.9 
4:1 383.7±3.8 382.3±3.1 374.4±5.9 380.1±4.4 
5:1 392.7±5.7 396.7±3.3 391.3±3.5 393.6±4.3 
6:1 Aggregate Aggregate Aggregate Aggregate 
7:1 Aggregate Aggregate Aggregate Aggregate 
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Table A-2: Chitosan-TPP nanoparticle zeta potential characterization. Medium MW chitosan, pH 5 and T=20±1°C. 
CS-TPP  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.5mg/mL 
3:1 37.37±1.13 37.46±0.96 37.08±0.62 37.30±0.93 
4:1 43.22±1.37 42.67±0.88 42.55±1.98 42.81±1.48 
5:1 45.43±0.53 45.33±0.83 45.01±0.95 45.26±0.79 
6:1 47.87±1.2 46.73±0.68 46.69±1.29 47.10±1.09 
7:1 Unstable Unstable Unstable Unstable 
Chitosan Concentration = 1.0mg/mL 
3:1 35.59±1.22 36.78±1.25 36.08±1.50 36.15±1.33 
4:1 40.97±1.32 41.24±1.12 40.71±0.60 40.97±1.05 
5:1 43.13±0.70 44.51±1.65 42.89±1.16 43.51±1.23 
6:1 45.14±1.52 44.76±1.40 45.61±0.92 45.17±1.31 
7:1 47.94±2.19 47.94±1.19 46.83±1.38 47.57±1.57 
Chitosan Concentration = 1.5mg/mL 
3:1 34.83±0.62 35.17±0.93 35.59±0.62 35.19±0.74 
4:1 39.52±0.88 41.79±0.74 40.52±0.91 40.61±0.85 
5:1 44.81±0.68 42.68±1.13 43.37±0.85 43.62±0.91 
6:1 42.37±0.92 42.82±0.99 43.83±1.75 43.01±1.28 
7:1 43.39±0.96 43.73±0.95 43.61±0.64 43.58±0.86 
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Table A-2 Continued 
CS-TPP  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 2.0mg/mL 
3:1 34.54±0.58 34.77±1.06 33.09±1.15 34.13±0.96 
4:1 39.12±1.89 39.54±1.39 40.05±1.02 39.57±1.48 
5:1 41.84±0.94 41.48±1.18 41.51±1.05 41.61±1.06 
6:1 43.44±0.92 42.93±0.80 43.49±0.73 43.29±0.82 
7:1 44.23±1.96 44.72±1.52 45.16±1.63 44.70±1.71 
Chitosan Concentration = 3.0mg/mL 
3:1 33.23±0.50 33.97±0.62 33.07±0.36 33.42±0.55 
4:1 38.63±0.92 37.81±0.49 37.92±1.15 38.12±0.90 
5:1 39.05±0.70 39.31±0.79 40.50±0.76 39.47±0.75 
6:1 Aggregate Aggregate Aggregate Aggregate 
7:1 Aggregate Aggregate Aggregate Aggregate 
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Table A-3: Chitosan-TPP nanoparticle polydispersity characterization. Medium MW chitosan, pH 5 and T=20±1°C. 
CS-TPP  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.5mg/mL 
3:1 0.290± 5.0e-3 0.271±0.011 0.263±7.0e-3 0.275±8.0e-3 
4:1 0.314± 9.0e-3 0.326± 0.010 0.324±8.0e-3 0.321±9.0e-3 
5:1 0.334± 0.011 0.359±5.0e-3 0.351±0.016 0.348±0.012 
6:1 0.379±0.014 0.378± 0.020 0.373±0.022 0.377±0.019 
7:1 Unstable Unstable Unstable Unstable 
Chitosan Concentration = 1.0mg/mL 
3:1 0.257±0.016 0.249±5.0e-3 0.264±5.0e-3 0.257±0.010 
4:1 0.301±6.0e-3 0.314±4.0e-3 0.306±8.0e-3 0.307±6.0e-3 
5:1 0.321±9.0e-3 0.337±6.0e-3 0.326±3.0e-3 0.328±6.0e-3 
6:1 0.339±8.0e-3 0.354±8.0e-3 0.355±8.0e-3 0.349±8.0e-3 
7:1 0.361±8.0e-3 0.358±9.0e-3 0.370±7.0e-3 0.363±8.0e-3 
Chitosan Concentration = 1.5mg/mL 
3:1 0.242±6.0e-3 0.243±0.014 0.218±0.013 0.234±0.012 
4:1 0.281±7.0e-3 0.280±0.010 0.281±7.0e-3 0.281±8.0e-3 
5:1 0.315±0.010 0.314±8.0e-3 0.293±0.014 0.307±0.011 
6:1 0.314±8.0e-3 0.319±4.0e-3 0.315±6.0e-3 0.316±6.0e-3 
7:1 0.284±5.0e-3 0.305±0.010 0.315±0.011 0.301±9.0e-3 
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Table A-3 Continued 
CS-TPP  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 2.0mg/mL 
3:1 0.257±0.010 0.261±0.012 0.269±0.015 0.262±0.013 
4:1 0.297±0.018 0.298±6.0e-3 0.296±0.012 0.297±0.013 
5:1 0.324±6.0e-3 0.321±0.019 0.315±0.013 0.320±0.014 
6:1 0.327±0.012 0.324±0.016 0.323±9.0e-3 0.325±0.013 
7:1 0.326±0.010 0.325±0.013 0.342±7.0e-3 0.331±0.010 
Chitosan Concentration = 3.0mg/mL 
3:1 0.287±0.014 0.272±0.013 0.277±0.012 0.279±0.013 
4:1 0.318±7.0e-3 0.301±9.0e-3 0.300±0.016 0.306±0.011 
5:1 0.319±6.0e-3 0.330±0.011 0.341±0.013 0.330±0.010 
6:1 Aggregate Aggregate Aggregate Aggregate 
7:1 Aggregate Aggregate Aggregate Aggregate 
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Table A-4: Chitosan-TPP nanoparticle solution pH study data. Medium MW chitosan, [CS] = 1mg/mL, CS:TPP = 3:1, pH 
5 and T=20±1°C.  
Solution pH Trial 1 Trial 2 Trial 3 Average 
Particle Diameter (nm) 
4.50 178.8±1.2 174.8±1.1 175.4±2.8 176.3±1.1 
4.75 182.1±2.1 183.3±1.5 183.5±2.0 183.0±1.9 
5.00 184.0±1.9 184.9±2.2 181.4±1.3 183.4±1.8 
5.25 171.9±1.4 171.0± 1.7 172.4±1.5 171.8±1.5 
5.50 165.2±1.4 165.6± 1.1 166.4± 0.7 165.7± 1.1 
5.75 172.9± 1.7 176.6± 1.1 175.2±1.4 174.9±1.4 
6.00 186.0±1.0 186.3±1.3 184.1±1.4 185.5±1.2 
6.25 185.3±1.8 184.0±2.1 185.3±2.0 184.9±2.0 
6.50 182.5±1.5 187.3±2.1 181.4±1.5 183.7±1.7 
Polydispersity 
4.50 0.311±6.0e-3 0.293±5.0e-3 0.302±5.0e-3 0.302±5.0e-3 
4.75 0.286±8.0e-3 0.297±6.0e-3 0.293±7.0e-3 0.292±7.0e-3 
5.00 0.301±6.0e-3 0.314±4.0e-3 0.306±8.0e-3 0.307±6.0e-3 
5.25 0.243±8.0e-3 0.244±7.0e-3 0.244±7.0e-3 0.244±7.0e-3 
5.50 0.201±0.011 0.195±0.012 0.213±6.0e-3 0.203±0.010 
5.75 0.235±9.0e-3 0.231±7.0e-3 0.239±8.0e-3 0.235±8.0e-3 
6.00 0.246±6.0e-3 0.270±9.0e-3 0.272±7.0e-3 0.263±7.0e-3 
6.25 0.257±0.010 0.247±7.0e-3 0.253±9.0e-3 0.252±9.0e-3 
6.50 0.265±9.0e-3 0.280±5.0e-3 0.251±0.010 0.265±8.0e-3 
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TableA-4 Continued 
Zeta Potential (mV) 
4.50 44.79±1.15 44.68±1.45 44.98±1.54 44.82±1.39 
4.75 41.69±1.80 42.43±1.35 41.46±1.68 41.86± 1.62 
5.00 40.97±1.32 41.24± 1.12 40.71± 0.60 40.97± 1.06 
5.25 36.95±1.29 37.94±1.69 37.75±1.66 37.55±1.56 
5.50 35.19±0.92 34.59±1.16 35.94±0.64 35.24±0.93 
5.75 32.29±1.41 31.57±1.20 32.53±1.38 32.13±1.33 
6.00 30.79±1.49 29.73±1.39 29.65±1.47 30.06±1.45 
6.25 25.05± 1.07 24.06± 1.71 25.31±1.57 24.81± 1.47 
6.50 21.30±1.18 21.40±1.10 22.20±1.43 21.63±1.24 
 
Figure A-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle diameter of chitosan-
TPP nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
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Figure A-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential of chitosan-TPP 
nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
 
Figure A-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity of chitosan-TPP 
nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
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Table A-5: Chitosan-TPP nanoparticle MW study, particle diameter characterization. [CS] = 1mg/mL, pH 5 and 
T=20±1°C. 
CS-TPP  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Trial 3 Average 
Low MW Chitosan 
3:1 92.1±0.8 89.5±0.4 87.6±0.6 90.2±0.4 
4:1 93.6±1.4 90.9±0.7 92.7±1.3 92.4±1.2 
5:1 99.8±2.7 93.3±0.6 98.5±2.3 97.2±2.1 
6:1 99.2±1.4 103.9±2.2 106.8±1.8 103.3±1.8 
7:1 113.2±2.6 116.0±2.6 117.7±4.4 115.6±3.3 
Medium MW Chitosan 
3:1 143.9±1.0 147.8±1.3 146.6±0.7 146.1±1.0 
4:1 176.9±2.6 175.3±2.3 176.9±2.5 176.4±2.5 
5:1 194.1±2.8 196.5±2.0 195.8±2.7 195.5±2.5 
6:1 209.1±2.9 211.6±3.5 211.3±3.2 210.7±3.2 
7:1 219.0±3.4 223.2±3.0 221.2±3.8 221.1±3.4 
High MW Chitosan 
3:1 183.0±2.5 182.0±1.9 183.5±1.6 182.8±2.0 
4:1 191.2±2.2 189.5±2.4 187.4±1.9 189.4±2.2 
5:1 188.1±3.0 189.5±2.3 188.0±2.6 188.5±2.6 
6:1 182.3±2.0 183.3±2.3 182.2±1.7 182.6±2.0 
7:1 180.7±2.2 182.5±3.2 181.2±3.2 181.5±2.9 
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Table A-6: Chitosan-TPP nanoparticle MW study, zeta potential characterization. [CS] = 1mg/mL, pH 5 and T=20±1°C. 
CS-TPP  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Trial 3 Average 
Low MW Chitosan 
3:1 32.04±1.21 31.29±1.81 30.87±2.19 31.40±1.78 
4:1 36.94±1.42 36.47±2.27 37.26±1.04 36.89±1.66 
5:1 39.95±1.29 39.81±1.57 40.47±1.48 40.07±1.45 
6:1 43.65±1.68 41.53±0.91 42.50±1.21 42.56±1.31 
7:1 42.13±0.85 41.48±0.90 42.34±1.50 41.98±1.12 
Medium MW Chitosan 
3:1 32.02±1.08 32.87±0.60 33.20±0.95 32.70±0.89 
4:1 39.10±1.11 40.35±0.85 40.48±1.06 39.98±1.01 
5:1 42.47±0.86 42.09±0.80 42.88±0.92 42.48±0.86 
6:1 42.81±1.01 44.02±1.79 44.17±1.46 43.67±1.56 
7:1 44.97±1.14 44.10±1.48 45.29±1.17 44.79±1.27 
High MW Chitosan 
3:1 35.12±0.87 36.12±1.07 36.41±0.94 35.88±0.96 
4:1 39.41±1.07 40.01±1.14 40.54±0.78 39.99±1.00 
5:1 40.74±1.44 40.48±1.77 40.73±0.70 40.65±1.38 
6:1 41.69±2.01 40.62±1.92 41.91±1.80 41.40±1.91 
7:1 43.30±1.23 42.08±1.31 43.12±1.22 42.83±1.25 
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Table A-7: Chitosan-TPP nanoparticle MW study, polydispersity characterization. [CS] = 1mg/mL, pH 5 and T=20±1°C. 
CS-TPP  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Trial 3 Average 
Low MW Chitosan 
3:1 0.225±7.0e-3 0.188±0.013 0.199±0.013 0.204±0.011 
4:1 0.241±8.0e-3 0.226±7.0e-3 0.252±6.0e-3 0.240±7.0e-3 
5:1 0.277±8.0e-3 0.261±0.011 0.300±7.0e-3 0.279±9.0e-3 
6:1 0.278±7.0e-3 0.292±5.0e-3 0.303±0.012 0.291±9.0e-3 
7:1 0.332±6.0e-3 0.323±8.0e-3 0.322±7.0e-3 0.326±7.0e-3 
Medium MW Chitosan 
3:1 0.234±6.0e-3 0.230±9.0e-3 0.235±8.0e-3 0.233± 8.0e-3 
4:1 0.311±4.0e-3 0.303±4.0e-3 0.300±4.0e-3 0.305±4.0e-3 
5:1 0.324±4.0e-3 0.318±3.0e-3 0.327±5.0e-3 0.323±4.0e-3 
6:1 0.355± 4.0e-3 0.345±7.0e-3 0.343±6.0e-3 0.348±6.0e-3 
7:1 0.357±6.0e-3 0.344±9.0e-3 0.355±8.0e-3 0.352±8.0e-3 
High MW Chitosan 
3:1 0.251±8.0e-3 0.248±0.012 0.249±8.0e-3 0.249±5.0e-3 
4:1 0.286±0.011 0.291±5.0e-3 0.283±0.011 0.287±9.0e-3 
5:1 0.311±8.0e-3 0.323±9.0e-3 0.299±0.013 0.311±0.010 
6:1 0.316±0.010 0.312±5.0e-3 0.314±4.0e-3 0.314±7.0e-3 
7:1 0.317± 6.0e-3 0.326±6.0e-3 0.341±7.0e-3 0.328±6.0e-3 
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Table A-8: Chitosan-carrageenan nanoparticle diameter characterization. Medium MW chitosan, pH 5 and T=20±1°C. 
CS-CG  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.125mg/mL 
2:1 208.6±3.9 202.3±1.7 198.2±3.0 203.0±3.0 
3:1 181.9±3.7 184.2±2.1 180.2±5.4 182.1±4.0 
4:1 405.4±33.1 394.2±28.7 368.6±24.6 389.4±29.0 
5:1 Aggregate Aggregate Aggregate Aggregate 
6:1 Aggregate Aggregate Aggregate Aggregate 
Chitosan Concentration = 0.25mg/mL 
2:1 253.0±2.4 248.5±2.1 247.9±1.9 249.8±2.1 
3:1 232.8±3.1 234.1±4.2 230.0±1.7 232.3±3.2 
4:1 210.9±2.6 216.8±2.9 210.4±2.5 212.7±2.7 
5:1 213.4±4.7 211.0±2.2 215.0±2.4 213.1±3.3 
6:1 224.6±2.4 227.8±3.1 226.2±3.7 226.2±3.1 
Chitosan Concentration = 0.5mg/mL 
2:1 340.1±4.4 339.0±4.5 333.1±3.8 337.4±4.2 
3:1 278.8±1.6 288.1±1.6 275.9±1.8 280.9±1.7 
4:1 266.7±1.8 265.4±2.3 259.6±1.4 263.9±1.9 
5:1 253.9±1.7 251.6±2.6 244.4±3.7 250.0±2.8 
6:1 241.8±3.7 252.3±2.3 255.6±2.0 250.0±2.8 
7:1 244.5±3.2 250.5±3.2 252.9±3.0 249.3±3.1 
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Table A-8 Continued 
CS-CG  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 1.0mg/mL 
2:1 495.6±8.8 504.1±7.7 500.4±7.5 500.0±8.0 
3:1 442.5±7.2 440.9±4.1 440.7±3.5 441.4±5.1 
4:1 390.0±3.9 397.4±5.9 398.8±5.9 395.4±5.3 
5:1 347.4±4.9 352.5±1.7 347.5±3.1 349.1±3.5 
6:1 349.6±4.7 354.2±5.6 348.0±4.1 350.6±4.8 
7:1 359.5±5.0 346.2±5.2 348.9±3.7 351.5±4.7 
 
Chitosan Concentration = 2.0mg/mL 
2:1 959.2±16.5 967.5±11.4 956.0±17.0 960.9±15.2 
3:1 701.1±6.5 699.9±6.7 704.8±9.5 701.9±7.7 
4:1 607.7±6.8 616.6±5.6 616.0±5.8 613.4±6.1 
5:1 513.8±5.9 510.1±6.6 519.2±7.3 514.4±6.8 
6:1 492.9±6.5 486.0±5.0 488.2±4.9 489.0±5.5 
7:1 452.3±4.4 462.8±4.2 448.9±4.5 454.7±4.4 
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Table A-9: Chitosan-carrageenan nanoparticle zeta potential characterization. Medium MW chitosan, pH 5 and 
T=20±1°C. 
CS-CG  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.125mg/mL 
2:1 44.20±0.62 44.35±1.62 44.30±1.23 44.28±1.23 
3:1 42.79±1.72 44.70±2.00 45.29±2.52 44.26±2.11 
4:1 45.80±1.59 44.72±1.68 43.67±1.90 44.74±1.75 
5:1 Aggregate Aggregate Aggregate Aggregate 
6:1 Aggregate Aggregate Aggregate Aggregate 
Chitosan Concentration = 0.25mg/mL 
2:1 48.28±1.88 49.82±1.19 48.79±0.63 48.96±1.34 
3:1 45.18±0.82 46.74±0.54 45.61±1.07 45.84±0.84 
4:1 44.93±2.04 46.94±1.88 46.05±2.29 45.97±1.96 
5:1 44.94±1.65 44.21±2.34 44.51±2.12 44.55±2.06 
6:1 45.00±1.39 44.89±0.73 44.76±2.17 44.88±1.55 
Chitosan Concentration = 0.5mg/mL 
2:1 49.52±0.77 47.34±0.76 47.92±1.31 48.26±0.98 
3:1 49.13±1.21 48.39±0.75 49.15±0.79 48.89±0.94 
4:1 52.26±1.00 52.16±0.88 49.51±0.90 51.31±0.93 
5:1 51.33±0.71 51.05±1.70 48.92±0.68 50.43±1.13 
6:1 48.78±1.39 50.36±1.88 49.27±1.78 49.47±1.70 
7:1 48.50±1.74 50.18±1.25 50.00±1.29 49.56±1.44 
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Table A-9 Continued 
CS-CG  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 1.0mg/mL 
2:1 47.17±0.97 46.42±0.79 46.60±1.09 46.73±0.96 
3:1 46.23±0.57 46.30±1.41 46.47±0.90 46.33±1.02 
4:1 47.10±1.25 45.80±0.96 46.63±0.82 46.51±1.03 
5:1 46.48±1.57 45.65±1.29 47.03±1.18 46.39±1.36 
6:1 44.84±0.98 44.97±1.28 45.47±1.61 45.09±1.32 
7:1 44.79±1.38 43.13±2.42 46.81±0.79 44.91±1.67 
Chitosan Concentration = 2.0mg/mL 
2:1 42.59±1.39 41.89±0.73 41.99±0.56 42.16±0.96 
3:1 45.88±0.49 44.23±0.89 46.94±0.83 45.68±0.76 
4:1 45.41±1.97 46.44±2.22 43.12±2.10 44.99±2.10 
5:1 47.40±2.55 45.20±2.11 45.60±3.00 46.07±2.58 
6:1 45.05±2.97 47.41±1.31 46.26±0.78 46.24±1.93 
7:1 45.96±1.76 46.10±2.47 44.04±1.16 45.37±1.87 
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Table A-10: Chitosan-carrageenan nanoparticle polydispersity characterization. Medium MW chitosan, pH 5 and 
T=20±1°C. 
CS-CG  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 0.125mg/mL 
2:1 0.280±5.0e-3 0.260±7.0e-3 0.266±7.0e-3 0.269±6.0e-3 
3:1 0.323±0.010 0.332±0.013 0.336±0.020 0.329±0.015 
4:1 0.376±0.053 0.400±0.012 0.368±0.017 0.381±0.033 
5:1 Aggregate Aggregate Aggregate Aggregate 
6:1 Aggregate Aggregate Aggregate Aggregate 
Chitosan Concentration = 0.25mg/mL 
2:1 0.251±0.011 0.217±0.021 0.268±5.0e-3 0.245±0.014 
3:1 0.290±7.0e-3 0.313±7.0e-3 0.269±7.0e-3 0.291±6.0e-3 
4:1 0.309±0.012 0.321±0.013 0.315±7.0e-3 0.315±0.011 
5:1 0.320±9.0e-3 0.341±0.013 0.328±0.016 0.325±0.013 
6:1 0.322±0.015 0.332±6.0e-3 0.339±9.0e-3 0.331±0.011 
Chitosan Concentration = 0.5mg/mL 
2:1 0.229±6.0e-3 0.247±5.0e-3 0.232±0.013 0.236±9.0e-3 
3:1 0.245±0.010 0.246±0.021 0.242±0.012 0.244±0.015 
4:1 0.269±9.0e-3 0.269±7.0e-3 0.282±9.0e-3 0.273±8.0e-3 
5:1 0.288±0.015 0.286±8.0e-3 0.277±0.011 0.284±0.011 
6:1 0.291±6.0e-3 0.305±0.015 0.291±8.0e-3 0.296±0.010 
7:1 0.297±0.012 0.320±6.0e-3 0.309±8.0e-3 0.309±9.0e-3 
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Table A-10 Continued 
CS-CG  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Trial 3 Average 
Chitosan Concentration = 1.0mg/mL 
2:1 0.223±0.021 0.249±0.010 0.232±0.017 0.235±0.017 
3:1 0.254±0.013 0.271±0.015 0.215±0.019 0.247±0.016 
4:1 0.226±0.017 0.223± 0.026 0.223±0.028 0.224±0.024 
5:1 0.255±0.013 0.247±0.022 0.235±0.024 0.246±0.020 
6:1 0.266±0.013 0.276±0.027 0.275±0.024 0.272±0.022 
7:1 0.272±0.010 0.279±0.018 0.264±0.022 0.272±0.017 
Chitosan Concentration = 2.0mg/mL 
2:1 0.282±0.019 0.277± 0.021 0.268±0.035 0.276±0.026 
3:1 0.264±0.024 0.257±0.023 0.263±0.020 0.261±0.022 
4:1 0.219±0.025 0.236±0.017 0.194±0.027 0.216±0.023 
5:1 0.248±0.025 0.212±0.021 0.205±0.021 0.222±0.022 
6:1 0.264±0.011 0.257±0.012 0.251±0.010 0.257±0.011 
7:1 0.255±0.015 0.251±0.023 0.247±0.014 0.251±0.018 
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Table A-11: Chitosan-carrageenan nanoparticle solution pH study data. Medium MW chitosan, [CS] = 0.5mg/mL, 
CS:CG= 4:1, pH 5 and T=20±1°C. 
Solution pH Trial 1 Trial 2 Trial 3 Average 
Particle Diameter (nm) 
4.50 318.7±5.5 317.0±2.4 311.6±1.9 315.8±3.6 
4.75 305.6±1.7 304.8±2.2 303.5±3.5 304.6±2.6 
5.00 295.9±2.8 303.0±2.3 296.9±1.9 298.6±2.4 
5.25 308.9±1.6 309.2±2.5 310.4±2.9 309.5±2.4 
5.50 314.9±1.7 314.6±2.5 318.8±4.8 316.1±3.3 
5.75 307.5±1.9 306.8±2.5 308.8±3.1 307.7±2.5 
6.00 300.7±1.4 298.8±2.6 296.2±2.4 298.6±2.2 
6.25 320. ±2.6 324.5±2.9 326.2±3.6 323.8±3.1 
6.50 338.0±4.0 341.3±2.8 338.7±3.3 339.3±3.4 
Polydispersity 
4.50 0.235±0.025 0.233±0.018 0.247±0.012 0.238±0.019 
4.75 0.234±0.021 0.235±0.020 0.239±0.018 0.236±0.020 
5.00 0.264±0.011 0.239±0.021 0.220±0.014 0.241±0.016 
5.25 0.239±0.018 0.245±0.021 0.228±0.015 0.237±0.018 
5.50 0.244±0.017 0.225±0.011 0.224±0.023 0.231±0.018 
5.75 0.235±0.017 0.228±0.013 0.226±0.015 0.230±0.015 
6.00 0.190±0.019 0.240±0.014 0.228±0.015 0.219±0.016 
6.25 0.226±0.021 0.218±0.019 0.229±0.016 0.224±0.019 
6.50 0.215±0.035 0.223±0.018 0.228±9.0e-3 0.222± 0.023 
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Table A-11 Continued 
Zeta Potential (mV) 
4.50 51.97±0.88 52.19±1.23 51.81±0.77 51.99±0.98 
4.75 50.75±0.78 49.81±1.11 49.25±0.69 49.94±0.88 
5.00 44.67±0.72 47.68±0.97 47.83±0.69 46.73±0.80 
5.25 46.46±0.71 44.34±0.84 45.79±0.91 45.53±0.82 
5.50 44.97±0.92 42.70±1.45 44.36±0.78 44.01±1.09 
5.75 40.56±0.88 38.67±1.14 39.42±1.18 39.55±1.07 
6.00 36.84±0.99 36.51±1.06 35.99±1.25 36.45±1.10 
6.25 32.34±1.16 31.54±1.05 33.15±1.21 32.34±1.14 
6.50 28.16±0.71 26.79±1.27 26.25±0.68 27.07±0.93 
 
Figure A-4: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean particle diameter of 
chitosan-carrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
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Figure A-5: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta potential of chitosan-
carrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
 
Figure A-6: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the polydispersity of chitosan-
carrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5. 
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Table A-12: Chitosan-carrageenan nanoparticle MW study, particle diameter characterization. [CS] = 0.5mg/mL, pH 5 
and T=20±1°C. 
CS-CG  
Mass Ratio 
Particle Diameter (nm) 
Trial 1 Trial 2 Average 
Low MW Chitosan 
2:1 248.3±4.1 254.9±3.2 251.6±3.7 
3:1 223.6±3.0 225.9±1.7 224.8±2.4 
4:1 204.6±2.9 204.3±3.6 204.5±3.3 
5:1 192.1±2.4 190.5±2.0 191.3±2.2 
6:1 191.8±2.1 188.8±3.1 190.3±2.6 
Medium MW Chitosan 
2:1 335.3±3.6 334.0±3.4 334.7±3.5 
3:1 294.1±3.6.0 299.5±3.8 296.8±3.7 
4:1 277.7±3.0 283.1±3.9 280.4±3.5 
5:1 284.7±4.8 285.4±4.8 285.1±4.8 
6:1 277.4±3.9 288.0±5.2 282.7±4.6 
High MW Chitosan 
2:1 339.1±1.4 355.4±2.0 347.3±1.7 
3:1 298.0±3.5 296.1±2.6 297.1±3.1 
4:1 268.6±2.6 272.8±3.0 270.7±2.8 
5:1 263.9±3.6 259.6±2.2 261.8±3.0 
6:1 247.4±4.2 251.9±4.6 249.7±4.4 
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Table A-13: Chitosan-carrageenan nanoparticle MW study, zeta potential characterization. [CS] = 0.5mg/mL, pH 5 and 
T=20±1°C. 
CS-CG  
Mass Ratio 
Zeta Potential (mV) 
Trial 1 Trial 2 Average 
Low MW Chitosan 
2:1 47.69±0.51 48.17±1.26 47.93±0.96 
3:1 46.99±1.06 45.88±1.88 46.44±1.53 
4:1 47.41±1.78 49.47±1.92 48.44±1.85 
5:1 47.23±2.58 48.00±1.73 47.62±2.20 
6:1 45.12±2.32 43.27±1.88 44.20±2.11 
Medium MW Chitosan 
2:1 50.58±1.39 48.51±0.88 49.55±1.16 
3:1 48.35±0.58 47.21±1.08 47.78±0.87 
4:1 50.04±1.98 51.04±0.98 50.54±1.56 
5:1 49.70±0.28 50.02±1.16 49.86±0.84 
6:1 44.17±3.31 47.35±3.29 45.76±3.30 
High MW Chitosan 
2:1 47.43±0.66 49.60±0.79 48.52±0.73 
3:1 46.77±0.58 47.97±0.66 47.37±0.62 
4:1 49.60±2.29 49.32±0.68 49.46±1.68 
5:1 48.77±2.20 48.35±1.96 48.06±2.08 
6:1 46.72±2.01 42.83±2.40 44.78±2.21 
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Table A-14: Chitosan-carrageenan nanoparticle MW study, polydispersity characterization. [CS] = 0.5mg/mL, pH 5 and 
T=20±1°C. 
CS-CG  
Mass Ratio 
Polydispersity 
Trial 1 Trial 2 Average 
Low MW Chitosan 
2:1 0.190±0.014 0.158± 0.013 0.174±0.014 
3:1 0.175±8.0e-3 0.193±0.011 0.184±0.010 
4:1 0.230±7.0e-3 0.214±0.013 0.222±0.010 
5:1 0.240±0.013 0.257±0.016 0.249±0.015 
6:1 0.266±7.0e-3 0.282±0.012 0.274±0.010 
Medium MW Chitosan 
2:1 0.257±0.012 0.249±0.010 0.253±0.011 
3:1 0.272±7.0e-3 0.274±8.0e-3 0.273±8.0e-3 
4:1 0.303±7.0e-3 0.277±8.0e-3 0.290±8.0e-3 
5:1 0.305±5.0e-3 0.307±8.0e-3 0.306±7.0e-3 
6:1 0.308±6.0e-3 0.339±0.010 0.324±8.0e-3 
High MW Chitosan 
2:1 0.174±0.019 0.186±8.0e-3 0.180±0.015 
3:1 0.211±0.016 0.236±0.012 0.224±0.014 
4:1 0.246±6.0e-3 0.248±0.013 0.247±0.010 
5:1 0.276±0.029 0.262±9.0e-3 0.269±0.022 
6:1 0.273±9.0e-3 0.286±0.010 0.280±0.010 
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B. Chitosan Nanoparticle Response Surface Modeling 
Table B-1: Chitosan-TPP nanoparticle RSM data. 
Process Factors Process Responses 
CS Conc. 
(mg/mL) 
CS:TPP 
Mass Ratio 
Solution pH 
Particle 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
Polydispersity 
0.5 3 5 103.2 37.08 0.263 
0.5 3 5 110.5 37.37 0.29 
0.5 3 5 106.7 37.46 0.271 
0.5 3 6 108.4 24.46 0.259 
0.5 3 6 110.3 24.25 0.258 
0.5 3 6 103.5 24.3 0.246 
0.5 4 5.5 137.1 35.1 0.245 
0.5 4 5.5 135.5 35.17 0.257 
0.5 4 5.5 139.8 34.49 0.247 
0.5 5 5 138.1 45.33 0.359 
0.5 5 5 142.9 45.43 0.334 
0.5 5 5 139.7 45.01 0.371 
0.5 5 6 167 30.58 0.35 
0.5 5 6 174.5 31.51 0.365 
0.5 5 6 178.2 31.75 0.342 
1 3 5.5 156.6 31.17 0.166 
1 3 5.5 158.4 31.32 0.166 
1 3 5.5 159.9 31.24 0.177 
1 4 5 184 40.97 0.301 
1 4 5 184.6 41.24 0.314 
1 4 5 181.4 40.71 0.306 
1 4 5.5 166.4 36.45 0.213 
1 4 5.5 165.2 35.19 0.201 
1 4 5.5 165.6 34.59 0.195 
1 4 6 186.3 29.73 0.27 
1 4 6 184.1 28.86 0.272 
1 4 6 186 30.79 0.246 
1 5 5.5 174.4 37.16 0.239 
1 5 5.5 165.3 37.44 0.236 
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Table B-1 Continue 
1 5 5.5 170.6 37.9 0.232 
1.5 3 5 227.3 34.83 0.242 
1.5 3 5 223.5 35.17 0.243 
1.5 3 5 220.3 35.59 0.218 
1.5 3 6 200.7 30.74 0.275 
1.5 3 6 203.6 30.47 0.272 
1.5 3 6 202.8 28.95 0.269 
1.5 4 5.5 207.2 38.74 0.252 
1.5 4 5.5 209.3 37.77 0.254 
1.5 4 5.5 215 38.07 0.258 
1.5 5 5 243 38.8 0.314 
1.5 5 5 245 39.42 0.293 
1.5 5 5 242.8 40.73 0.314 
1.5 5 6 234.4 35.88 0.307 
1.5 5 6 235 35.41 0.327 
1.5 5 6 230.5 35.21 0.324 
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Table B-2: Chitosan-carrageenan nanoparticle RSM data. 
Process Factors Process Responses 
CS Conc. 
(mg/mL) 
CS:CG   
Mass Ratio 
Solution pH 
Particle 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
Polydispersity 
0.5 3 4.5 318.7 51.97 0.235 
0.5 3 4.5 317 51.19 0.233 
0.5 3 4.5 311.6 51.81 0.247 
0.5 3 5.5 314.9 44.97 0.244 
0.5 3 5.5 314.6 41.89 0.225 
0.5 3 5.5 318.8 44.36 0.224 
0.5 5 4.5 274.5 48.02 0.314 
0.5 5 4.5 273.3 48.92 0.336 
0.5 5 4.5 276 50.06 0.305 
0.5 5 5.5 268.3 41.59 0.298 
0.5 5 5.5 264.5 41.86 0.303 
0.5 5 5.5 263.1 41.53 0.333 
0.5 4 5 266.7 52.26 0.269 
0.5 4 5 265.4 52.16 0.269 
0.5 4 5 259.6 49.51 0.282 
0.75 3 5 357.6 48.96 0.221 
0.75 3 5 360.6 50.12 0.22 
0.75 3 5 353.8 49.64 0.236 
0.75 4 5 328 44.72 0.241 
0.75 4 5 328.8 45.77 0.265 
0.75 4 5 330 44.52 0.234 
0.75 5 5 301.9 44.69 0.258 
0.75 5 5 305.9 44.65 0.259 
0.75 5 5 294.7 44.35 0.259 
0.75 4 4.5 346.4 48.36 0.26 
0.75 4 4.5 335.4 50.71 0.263 
0.75 4 4.5 346.3 50.57 0.235 
0.75 4 5.5 328.5 41.57 0.26 
0.75 4 5.5 328.1 44.71 0.26 
0.75 4 5.5 325.4 41.52 0.26 
1 3 4.5 404.7 48.67 0.228 
1 3 4.5 401.6 48.25 0.203 
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Table B-2 Continued 
1 3 4.5 396.5 47.31 0.248 
1 3 5.5 393.6 40.6 0.234 
1 3 5.5 398 37.51 0.213 
1 3 5.5 399.9 37.58 0.205 
1 5 4.5 344.7 49.28 0.272 
1 5 4.5 346.2 45.89 0.275 
1 5 4.5 353.1 47.47 0.262 
1 5 5.5 345.7 41.03 0.256 
1 5 5.5 355 41.33 0.255 
1 5 5.5 351.6 39.5 0.213 
1 4 5 390 47.1 0.226 
1 4 5 397.4 45.8 0.223 
1 4 5 398.8 46.63 0.223 
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C. Encapsulation and Controlled Release of rHu-EPO 
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Figure C-1: Example of rHu-EPO fluorometer intensity readings used in creation of calibration curve. 
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Figure C-2: Example of rHu-EPO calibration curve applied for conversion of intensity to concentration. 
 
Table C-1: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, cumulative mass release (µg/mL). 
Time (h) 
Cumulative Mass of rHu-EPO Released (µg/mL) 
Low MW Medium MW High MW 
3 2.07±0.01 1.86±0.01 1.57±0.01 
6 3.67±0.51 3.01±0.05 2.48±0.10 
12 4.69±1.10 3.77±0.17 2.78±0.13 
24 ~ 4.06±0.41 3.51±0.20 
36 5.79±1.19 5.01±0.34 3.78±0.58 
60 6.66±0.47 5.71±0.23 4.54±0.57 
84 7.19±0.93 6.02±0.15 5.44±0.24 
156 7.83±0.53 6.96±0.21 5.82±0.86 
252 9.14±0.01 7.75±0.26 6.51±0.32 
324 10.46±0.05 9.03±0.27 7.49±0.02 
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Table C-2: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, percent release. 
Time (h) 
 rHu-EPO Released (%) 
Low MW Medium MW High MW 
3 17.28±0.07 13.90±0.26 11.20±0.07 
6 30.67±4.27 22.53±2.17 17.63±0.73 
12 39.15±9.17 26.86±1.96 19.75±0.91 
24 ~ 30.35±2.81 24.93±1.42 
36 48.33±9.96 33.79±1.96 26.86±4.13 
60 55.56±3.88 39.07±1.74 32.26±4.02 
84 60.00±7.80 45.03±3.20 38.65±1.66 
156 65.34±4.46 48.43±0.95 41.37±6.10 
252 76.31±0.10 53.15± 0.82 46.29±2.29 
324 87.32±0.44 60.26±0.83 53.23±0.15 
 
 
Figure C-3: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-TPP nanoparticles produced 
using low, medium and high MW chitosan. [CS] = 0.6mg/mL, CS:TPP = 4:1, pH 5.2 and T= 20±1°C. 
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Table C-3: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticles, cumulative mass release (µg/mL). 
Time (h) 
Cumulative Mass of rHu-EPO Released (µg/mL) 
~30mV NPs ~35mV NPs ~40mV NPs 
3 2.58±0.01 2.32±0.02 1.86±0.01 
6 4.21±0.01 3.67±0.01 3.01±0.05 
12 4.92±0.01 4.44±0.02 3.77±0.17 
24 ~ ~ 4.06±0.41 
36 6.79±0.01 5.96±0.04 5.01±0.34 
60 7.32±0.01 6.58±0.12 5.71±0.23 
84 7.75±0.01 7.12±0.13 6.02±0.15 
156 8.40±0.01 8.06±0.07 6.96±0.21 
252 9.04±0.01 9.01±0.02 7.75±0.26 
324 9.36±0.01 9.52±0.09 9.03±0.27 
 
 
Table C-4: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticles, percent release. 
Time (h) 
 rHu-EPO Released (%) 
~30mV NPs ~35mV NPs ~40mV NPs 
3 23.85±0.14 18.97± 0.13 13.90±0.26 
6 38.93±0.07 30.08±0.01 22.53±2.17 
12 45.55±0.01 36.37±0.20 26.86±1.96 
24 ~ ~ 30.35±2.81 
36 62.85±0.01 48.77±0.29 33.79±1.96 
60 67.71±0.01 53.90±0.97 39.07±1.74 
84 71.74±0.11 58.29±1.07 45.03±3.20 
156 77.71±0.08 65.98±0.54 48.43±0.95 
252 83.72±0.02 73.76±0.16 53.15±0.82 
324 86.60±0.11 77.96±0.72 60.26±0.83 
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Figure C-4: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-TPP nanoparticles with 
surface charges of ~30mV, ~35mV and ~40mV. Medium MW chitosan (200cP – 400cP), T= 20±1°C. 
 
Table C-5: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles, cumulative mass release 
(µg/mL). 
Time (h) 
Cumulative Mass of rHu-EPO Released (µg/mL) 
Low MW Medium MW High MW 
3 2.01±0.08 1.58±0.13 1.27±0.03 
6 2.75±0.09 2.16±0.09 1.92±0.01 
12 3.57±0.04 2.71±0.02 2.57±0.01 
24 ~ 3.55±0.14 3.16±0.03 
36 4.80±0.38 4.33±0.06 3.77±0.11 
60 5.50±0.18 5.02±0.10 4.34±0.14 
84 6.13±0.18 5.45±0.08 5.04±0.08 
156 6.67±0.14 6.10±0.18 5.51±0.14 
252 7.66±0.19 6.73±0.29 6.17±0.09 
324 8.56±0.08 7.37±0.24 6.81±0.16 
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Table C-6: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles, percent release. 
Time (h) 
 rHu-EPO Released (%) 
Low MW Medium MW High MW 
3 18.31±0.23 10.70±0.86 10.14±0.81 
6 25.99±0.57 14.62±0.61 13.85±0.58 
12 30.67±0.34 18.35±0.14 17.38±0.14 
24 ~ 24.02±0.95 22.76±0.90 
36 37.78±0.49 29.33±0.40 27.79±0.38 
60 43.74±1.77 33.98±0.65 32.20±0.62 
84 47.98±2.94 36.89±0.54 34.96±0.52 
156 53.72±2.34 41.33±1.24 39.16±1.17 
252 58.86±1.87 45.58±1.93 43.19±1.83 
324 67.36±0.58 49.96±1.64 47.34±1.55 
 
 
Figure C-5:Comparison of the cumulative mass of rHu-EPO released over time for chitosan-carrageenan nanoparticles 
produced using low, medium and high MW chitosan. [CS] = 0.5mg/mL, CS:CG = 3:1, 5.0 pH and T= 20±1°C. 
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Table C-7: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles, cumulative mass release 
(µg/mL). 
Time (h) 
Cumulative Mass of rHu-EPO Released (µg/mL) 
~40mV NPs ~45mV NPs ~50mV NPs 
3 2.50±0.03 1.88±0.03 1.58±0.13 
6 3.55±0.08 2.77±0.07 2.16±0.09 
12 4.19±0.05 3.43±0.01 2.71±0.02 
24 ~ ~ 3.55±0.14 
36 5.16±0.07 4.58±0.14 4.33±0.06 
60 5.97±0.24 5.30±0.25 5.02±0.10 
84 6.55±0.40 6.26±0.06 5.45±0.08 
156 7.33±0.32 7.05±0.42 6.10±0.18 
252 8.03±0.26 7.68±0.64 6.73±0.29 
324 9.20±0.08 8.43±0.62 7.37±0.24 
 
Table C-8: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles, percent release. 
Time (h) 
 rHu-EPO Released (%) 
~40mV NPs ~45mV NPs ~50mV NPs 
3 19.22±0.24 13.64±0.19 10.70±0.86 
6 27.27±0.59 20.11±0.53 14.62±0.61 
12 32.18±0.36 24.90±0.06 18.35±0.14 
24 ~ ~ 24.02±0.95 
36 39.64±0.52 33.24±1.01 29.33±0.40 
60 45.90±1.85 38.53±1.81 33.98±0.65 
84 50.35±3.09 45.48±0.44 36.89±0.54 
156 56.37±2.46 51.21±3.05 41.33±1.24 
252 61.76±1.96 55.78±4.62 45.58±1.93 
324 70.68±0.61 61.26±4.49 49.96±1.64 
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Figure C-6: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-carrageenan nanoparticles 
with surface charges of ~40mV, ~45mV and ~50mV. Medium MW chitosan (200cP – 400cP), T= 20±1°C. 
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